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 Abstract 
 This study was carried out in Khartoum State to determine Hepatitis B virus DNA 
(HBV DNA) by PCR, and to correlate it with serological markers, in samples positive for 
HBsAg, and to determine sero-prevalence of HBV in Khartoum state using HBsAg 
ELISA. And to determine sero-prevalence of HCV in HBV patients (co-infection with 
hepatitis C virus) 
         Blood sample were randamlly collected from 280 blood donors, 20 multi-transfused 
individuals, 100 haemodialysis patients and 80 jaundiced patients. 
 Polymerase chain reaction technique (PCR) was used to detect HBV-DNA using 
oligonucleotide primers for surface antigen genome region specific (ss genome region 
specific) and serologic tests for HBV were performed retrospectively. 
 Eleven (68.7%) out of 16 blood donors were positive for HBV-DNA, two (100%) 
out of 20 multi-transfused patients were positive, 23 (100%) out of 100 haemodialysis 
patients were positive and 9 (100%) out of 80 jaundiced patients were positive for HBV-
DNA.  
 More over, the PCR detected two (20%) positive HBV DNA out of 10 samples 
collected from blood donors that were negative for HBsAg by ICT and ELISA tests. 
           This result suggests that, detection of HBV DNA by amplification technique 
serves as an important supplementary tool besides serology in a number of clinical 
settings, especially in determining low levels of viraemia in patients with non-replicative 
HBV disease and chronic hepatitis, and also in a few patients with past HBV infection 
who could be asymptomatic carriers of HBV infection. 
 Immuno-chromatography technique (ICT), direct sandwich ELISA test were used 
to detect HBsAg and indirect ELISA to detect HCV-anti bodies in samples positive for 
HBsAg.  
 Fifteen (5.3%) out of 100 blood donors were positive for HBsAg by ICT, whereas 
sixteen (5, 7%) out of 100 blood donors were positive by HBsAg ELISA test. In multi-
transfused patients only two (10%) out of 20 patients were found positive by both 
techniques. In haemodialysis patients twenty three (23%) out of 100 patients were found 
positive by both techniques. In jaundiced patients nine (11.2%) out of 80 patients were 
found positive by both techniques.  
 In various group studied out of 480 samples. ELISA test was able to detect the 
presence of HBsAg in 50 (10.4%) individuals. but by using ICT test 49 (10.2%) HBsAg 
positive individuals were detected. However, there was a very high agreement between 
ICT and ELISA and no statistical significant difference was obtained by the application 
of Stata NT/98 and both assays were sensitive, specific and reliable 
 Also the HCV-antibodies were detected in samples positive for HBsAg as co-
infection in three (6%) out of 50 HBsAg positive. using indirect HCV-ELISA test using 
recombinant antigens. and ICT test. 
 out of 16 HBsAg positive blood donors. One (6.6%) was positive for HCV-
antibodies by ICT, whereas two (12.5%) HBsAg positive blood donors were positive by 
HCV-ELISA test. In haemodialysis group only one (4.3%) out of 23 patients was found 
positive by both techniques,  
 multi-transfused and jaundiced patients were found negative for HCV-antibodies by both 
techniques.  
 In this study haemodialysis machine (46%) sharing needles (14%), sexual practice 
(12%), blood transfused (66%) and probably surgical instruments (30%) represent risk 
factors for transmission of HBV infection. Tattooing and intravenous drug users seem to 
have no role in predisposition to the disease in this study.  
 In this study only 4 (8%) patients have background about how HBV is transmitted 
and how it is prevented. According to the data obtained from the questionnaire this is 
probably due to the lack of professional and public education. In this study it has been 
found that infection with hepatitis virus may be predisposed by more than one risk 
factors.  
 
  
 
 
 
 
  ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ
 
 اﻷﻃﺮوﺣﺔ ﻣﻠﺨﺺ
ﺃﺠﺭﻴﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻓﻲ ﻭﻻﻴﺔ ﺍﻟﺨﺭﻁﻭﻡ ﻟﺘﺤﺩﻴﺩ ﺍﻟﺤﺎﻤﺽ ﺍﻟﻨﻭﻭﻱ ﻟﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ
ﻭﺍﻴﻀﺎﹰ ﻤﺩﻯ ﺍﻨﺘﺸﺎﺭ ﺍﻹﻨﺘﻴﺠﻨﺎﺕ ﻟﻬﺫﺍ ﺍﻟﻔﻴﺭﻭﺱ ﻓﻲ ﻤﺠﻤﻭﻋﺎﺕ ﻤﺨﺘﻠﻔﺔ ﻭﺍﻴﻀﺎﹰ ﻟﺘﺤﺩﻴﺩ ﻤﺩﻯ(.ﺏ)ﻨﻭﻉ 
ﻓﻲ ﺍﻟﻤﺭﻀﻰ ﺍﻟﻤﺼﺎﺒﻴﻥ ﺒﻔﻴﺭﻭﺱ( ﺝ)ﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ ﺍﻨﺘﺸﺎﺭ ﺍﻷﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍ
ﻟﻤﻌﺭﻓﺔ ﻤﺩﻯ ﺃﻨﺘﺸﺎﺭ ﺍﻹﺼﺎﺒﺔ ﺍﻟﻤﺯﺩﻭﺠﺔ ﺒﻔﻴﺭﻭﺴﺎﺕ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ( ﺏ)ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ 
  (.ﺝ)ﻭ( ﺏ)ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ 
  :ﺘﻡ ﺠﻤﻊ ﻋﻴﻨﺎﺕ ﻤﻥ ﺍﻟﺩﻡ ﻋﺸﻭﺍﺌﻴﺎﹰ ﻤﻥ ﻤﺠﻤﻭﻋﺎﺕ ﻤﺨﺘﻠﻔﺔ ﺘﺸﻤل
 ﻋﻴﻨﺔ02ﻋﻴﻨﺔ ﺩﻡ ﻤﻥ ﻤﺭﻀﻰ ﺍﻟﻐﺴﻴل ﺍﻟﺩﻤﻭﻱ ﻭ  001ﻋﻴﻨﺔ ﺩﻡ ﻤﻥ ﺍﻷﺸﺨﺎﺹ ﺍﻟﻤﺘﺒﺭﻋﻴﻥ ﺒﺎﻟﺩﻡ ﻭ 082
  . ﻋﻴﻨﺔ ﺩﻡ ﻤﻥ ﻤﺭﻀﻰ ﺍﻟﻴﺭﻗﺎﻥ08ﻤﻥ ﻤﺭﺓ ﻭ  ﻤﻥ ﺃﺸﺨﺎﺹ ﺘﻡ ﻟﻬﻡ ﻨﻘل ﺩﻡ ﺃﻜﺜﺭ
 اﺳﺘﺨﻼص ﺒﻌﺩ )RCP(ﺃﺠﺭﻯ ﺍﻻﺨﺘﺒﺎﺭ ﻟﺘﺤﺩﻴﺩ ﺍﻟﺤﺎﻤﺽ ﺍﻟﻨﻭﻭﻱ ﺒﻭﺍﺴﻁﺔ ﺘﻔﺎﻋل ﺍﻟﺒﻠﻤﺭﺓ ﺍﻟﻤﺘﺴﻠﺴل
 ﺗﻔﺎﻋﻞ.ﻨﻮلﻋﻦ ﻃﺮﻳﻖ اﻟﻜﻠﻮروﻓﻮرم واﻟﻔﻴ ﻟﻠﻔﻴﺮوس( AND)اﻷوآﺴﺠﻴﻦ اﻟﺤﻤﺾ اﻟﻨﻮوى ﻣﻨﻘﻮص 
ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻣﺮض ادﺧﻞ آﻮﺳﻴﻠﺔ ﺣﺪﻳﺜﺔ ﻟﺘﺸﺨﻴﺺ اﻟﺒﻠﻤﺮة اﻟﻤﺘﺴﻠﺴﻞ اﻟﻤﺴﺘﺨﺪم ﻓﻰ هﺬ ﻩ اﻟﺪراﺳﺔ
ﺍﺴﺘﻌﻤل ﺘﻘﻨﻴﺔ( ﺝ)ﻭﻟﺘﺤﺩﻴﺩ ﺍﻷﻨﺘﻴﺠﻴﻥ ﺍﻟﺴﻁﺤﻲ ﻟﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ (. ﺏ)ﻤﻥ ﻨﻭﻉ 
ل ﺘﻘﻨﻴﺔ ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ ﺍﻟﻤﻤﻨﻊﻭﺃﻴﻀﺎﹰ ﺍﺴﺘﻌﻤ( ﺍﻟﺴﺎﻨﺩﻭﺘﺵ)ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ ﺍﻟﻤﻤﻨﻊ ﻭﺍﻷﻟﻴﺯﺍ ﺍﻟﻤﺒﺎﺸﺭﺓ 
  (.ﺝ)ﻭﺍﻷﻟﻴﺯﺍ ﻏﻴﺭ ﺍﻟﻤﺒﺎﺸﺭ ﻟﺘﺤﺩﻴﺩ ﺍﻹﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ 
ﻤﻥ%( 001)ﻤﻥ ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺘﺒﺭﻋﻴﻥ ﻭﺃﺜﻨﻴﻥ %( 7.86)ﺒﻌﺩ ﺇﺠﺭﺍﺀ ﺍﻻﺨﺘﺒﺎﺭﺍﺕ ﻭﺠﺩ ﺃﻥ ﺃﺤﺩﻯ ﻋﺸﺭﺓ 
ﻤﻥ ﻤﺠﻤﻭﻋﺔ%( 001 )ﻤﺠﻤﻭﻋﺔ ﺍﻷﺸﺨﺎﺹ ﺍﻟﺫﻴﻥ ﺘﻡ ﻟﻬﻡ ﻨﻘل ﺩﻡ ﺃﻜﺜﺭ ﻤﻥ ﻤﺭﺓ ﻭﺜﻼﺙ ﻭﻋﺸﺭﻭﻥ
ﻤﻥ ﻤﺠﻤﻭﻋﺔ ﻤﺭﻀﻰ ﺍﻟﻴﺭﻗﺎﺕ ﻤﻭﺠﺒﺔ ﻟﻠﺤﻤﺽ ﺍﻟﻨﻭﻭﻱ%( 001)ﻤﺭﻀﻰ ﺍﻟﻐﺴل ﺍﻟﺩﻤﻭﻱ ﻭﺘﺴﻊ 
  (.RCP)ﺒﺎﺴﺘﺨﺩﺍﻡ ﺘﻔﺎﻋل ﺍﻟﺒﻠﻤﺭﺓ ﺍﻟﻤﺘﺴﻠﺴل( ﺏ)ﻟﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ 
ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﺘﻲ ﺘﻤﺕ ﺩﺭﺍﺴﺘﻬﺎ ﺨﻤﺴﻭﻥ ﻋﻴﻨﺔ ﻤﻭﺠﺒﺔ ﻟﻸﻨﺘﻴﺠﻴﻥ ﺍﻟﺴﻁﺤﻲ ﻟﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ
 ﻓﻰ ﺘﺤﺩﻴﺩ ﺨﻤﺴﺔ ﻭﺍﺭﺒﻌﻭﻥ)RCP( ﺍﺴﺘﻁﺎﻉ ﺃﺨﺘﺒﺎﺭ ﺘﻔﺎﻋل ﺍﻟﺒﻠﻤﺭﺓ ﺍﻟﻤﺘﺴﻠﺴل( ﺏ)ﺌﻲ ﻤﻥ ﻨﻭﻉ ﺍﻟﻭﺒﺎ
ﻤﻥ%( 3.5)ﻋﻴﻨﺔ ﻤﻭﺠﺒﺔ ﻟﻠﺤﻤﺽ ﺍﻟﻨﻭﻭﻱ ﻟﻠﻔﻴﺭﻭﺱ، ﺍﻴﻀﺎﹰ ﻭﺠﺩ ﺃﻥ ﺜﻼﺙ ﻭﻋﺸﺭﻭﻥ ﻋﻴﻨﺔ %( 09)
ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺘﺒﺭﻋﻴﻥ ﻟﻠﺩﻡ ﻤﻭﺠﺒﺔ ﻟﻸﻨﺘﻴﺠﻴﻥ ﺍﻟﺴﻁﺤﻲ ﻟﻠﻔﻴﺭﻭﺱ ﺒﺎﺴﺘﻌﻤﺎل ﺘﻘﻨﻴﺔ ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ ﺍﻟﻤﻤﻨﻊ
ﺍﻤﺎ ﻓﻲ.ﻤﻭﺠﺒﺔ ﻤﻥ ﻨﻔﺱ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻷﻟﻴﺯﺍ ﺍﻟﺴﺎﻨﺩﻭﺘﺵ ﺍﻟﻤﺒﺎﺸﺭ%( 6.5 )ﻭﺴﺕ ﻋﺸﺭﺓ
ﻤﻭﺠﺒﺔ ﺒﺎﺴﺘﺨﺩﺍﻡ%( 51) ﻤﺠﻤﻭﻋﺔ ﺍﻷﺸﺨﺎﺹ ﺍﻟﺫﻴﻥ ﺘﻡ ﻟﻬﻡ ﻨﻘل ﺩﻡ ﺃﻜﺜﺭ ﻤﻥ ﻤﺭﺓ ﻭﺠﺩﺕ ﻋﻴﻨﺘﺎﻥ 
ﻤﻭﺠﺒﺔ%( 32)ﺍﻟﺘﻘﻨﻴﻴﻥ ﺃﻤﺎ ﻓﻲ ﻤﺠﻤﻭﻋﺔ ﻤﺭﻀﻰ ﺍﻟﻐﺴﻴل ﺍﻟﺩﻤﻭﻱ ﻭﺠﺩﺕ ﺜﻼﺙ ﻭﻋﺸﺭﻭﻥ ﻋﻴﻨﺔ 
ﻤﻭﺠﺒﺔ ﺒﺎﺴﺘﺨﺩﺍﻡ%( 2.11)ﻤﻭﻋﺔ ﻤﺭﻀﻰ ﺍﻟﻴﺭﻗﺎﺕ ﻭﺠﺩﺕ ﺘﺴﻊ ﻋﻴﻨﺎﺕ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻟﺘﻘﻨﻴﻴﻥ ﺃﻤﺎ ﻓﻲ ﻤﺠ
  .ﺍﻟﺘﻘﻨﻴﺘﻴﻥ
ﻋﻴﻨﺔ%( 4.01)ﻋﻴﻨﺔ ﺘﻡ ﺍﻻﻜﺘﺸﺎﻑ ﻋﻥ ﺨﻤﺴﻭﻥ ( 084)ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻤﺨﺘﻠﻔﺔ ﺍﻟﺘﻲ ﺘﻤﺕ ﺩﺭﺍﺴﺘﻬﺎ 
%(2.01)ﻤﻭﺠﺒﺔ ﻜﺎﻷﻨﺘﻴﺠﻴﻥ ﺍﻟﺴﻁﺤﻲ ﺒﻭﺍﺴﻁﺔ ، ﺃﺨﺘﺒﺎﺭ ﺍﻷﻟﻴﺯﺍ ﺍﻟﺴﺎﻨﺩﻭﺘﺵ ﺍﻟﻤﺒﺎﺸﺭ ﻭﺘﺴﻊ ﻭﺍﺭﺒﻌﻭﻥ 
ﻭﺠﺩ ﻫﺫﺍ ﺍﻟﻔﺭﻕ ﻏﻴﺭ ﻤﻌﻨﻭﻱ ﻋﻨﺩ ﺘﺤﻠﻴل ﺍﻟﺒﻴﺎﻨﺎﺕ. ﺘﻘﻨﻴﺔ ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ ﺍﻟﻤﻤﻨﻊﻋﻴﻨﺔ ﻤﻭﺠﺒﺔ ﺒﻭﺍﺴﻁﺔ
ﻭﺒﺎﻟﺘﺎﻟﻲ ﻓﺈﻥ ﻜﻼ ﺍﻷﺨﺘﺒﺎﺭﻴﻥ( ) )citsitats appaK( 89/TN atatSﺃﺤﺼﺎﺌﻴﺎﹰ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺒﺭﻨﺎﻤﺞ 
  (.ﺏ)ﻴﻤﻜﻥ ﺍﻹﻋﺘﻤﺎﺩ ﻋﻠﻴﻬﻤﺎ ﻓﻲ ﻜﺸﻑ ﺍﻷﻨﺘﻴﺠﻴﻥ ﺍﻟﺴﻁﺢ ﻟﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ 
ﻓﻲ( ﺝ)ﺸﻑ ﻋﻥ ﺍﻷﺠﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﺒﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ         ﻭﺍﻴﻀﺎﹰ ﺘﻡ ﺍﻟﻜ
ﻟﺘﺤﺩﻴﺩ ﻤﺩﻯ ﺃﻨﺘﺸﺎﺭ( ﺏ)ﺍﻟﻌﻴﻨﺎﺕ ﺍﻟﻤﻭﺠﺒﺔ ﻜﺎﻷﻨﺘﻴﺠﻴﻥ ﺍﻟﺴﻁﺤﻲ ﺒﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ 
ﺒﻭﺍﺴﻁﺔ ﺃﺨﺘﺒﺎﺭ ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ ﺍﻟﻤﻤﻨﻊ ﻭﺍﻷﻟﻴﺯﺍ ﻏﻴﺭ ﺍﻟﻤﺒﺎﺸﺭ( ﺏ)ﺍﻷﺼﺎﺒﺔ ﺍﻟﻤﺯﺩﻭﺠﺔ ﺒﻔﻴﺭﻭﺱ 
ﻤﻥ ﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺘﺒﺭﻋﻴﻥ ﺒﺎﻟﺩﻡ ﺒﺎﺴﺘﻌﻤﺎل ﺘﻘﻨﻴﺔ ﺍﻟﻜﺭﻭﻤﺎﺘﻭﻏﺭﺍﻓﻲ%( 6.6)ﺩﺓ ﻭﺠﺩﺕ ﺃﻥ ﻋﻴﻨﺔ ﻭﺍﺤ
ﻭﻋﻴﻨﺎﺕ. ﺍﻟﻤﻤﻨﻊ
ﺃﻤﺎ ﻓﻲ ﻤﺠﻤﻭﻋﺔ ﻤﺭﻀﻰ. ﻤﻭﺠﺒﺔ ﻤﻥ ﻨﻔﺱ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻷﻟﻴﺯﺍ ﻏﻴﺭ ﺍﻟﻤﺒﺎﺸﺭﺓ%( 5.21 )
ﺒﻴﻨﻤﺎ ﻟﻡ ﻴﺘﻡ ﺍﻟﻜﺸﻑ ﻋﻥ. ﻤﻭﺠﺒﺔ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺍﻟﺘﻘﻨﻴﺘﻴﻥ%( 3.4)ﺍﻟﻐﺴﻴل ﺍﻟﺩﻤﻭﻱ ﻭﺠﺩﺕ ﻋﻴﻨﺔ ﻭﺍﺤﺩﺓ 
ﻓﻲ ﻤﺠﻤﻭﻋﺔ ﺍﻷﺸﺨﺎﺹ ﺍﻟﺫﻴﻥ ﺘﻡ ﻟﻬﻡ ﻨﻘل ﺩﻡ( ﺝ)ﻟﻤﻀﺎﺩﺓ ﻟﻔﻴﺭﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﺍﻷﺠﺴﺎﻡ ﺍ
  .ﺃﻜﺜﺭ ﻤﻥ ﻤﺭﺓ ﻭﻤﺠﻤﻭﻋﺔ ﻤﺭﻀﻰ ﺍﻟﻴﺭﻗﺎﺕ
ﻭﺍﺴﺘﻌﻤﺎل%( 66)ﻭﻨﻘل ﺍﻟﺩﻡ %( 64)ﻓﻲ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻭﺠﺩ ﺃﻥ ﻤﺎﻜﻴﻨﺔ ﺍﻟﻐﺴﻴل ﺍﻟﺩﻤﻭﻱ              
 ﺭﺒﻤﺎ ﺘﻤﺜل ﻋﻭﺍﻤل .%(03) ﺔﻭﺃﺩﻭﺍﺕ ﺍﻟﺠﺭﺍﺤ%( 21)ﻭﻤﻤﺎﺭﺴﺔ ﺍﻟﺠﻨﺱ %( 41)ﺍﻷﺩﻭﺍﺕ ﺍﻟﻤﻠﻭﺜﺔ 
ﻟﻠﺨﻁﻭﺭﺓ ﻓﻲ ﻨﻘل ﺍﻟﻤﺭﺽ ، ﺒﻴﻨﻤﺎ ﺍﻟﻭﺸﻡ ﻭﺍﻹﺒﺭ ﺍﻟﻤﺨﺩﺭﺓ ﺭﺒﻤﺎ ﻟﻡ ﻴﻠﻌﺒﺎ ﺩﻭﺭﺍﹰ ﻓﻲ ﺃﻨﺘﺸﺎﺭ ﺍﻟﻤﺭﺽ ﻓﻲ
  . ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻤﺨﺘﻠﻔﺔ ﺍﻟﺘﻲ ﺘﻤﺕ ﺩﺭﺍﺴﺘﻬﺎ
ﻓﻘﻁ ﻤﻥ ﻤﺠﻤﻭﻋﺔ ﺍﻟﺨﻤﺴﻴﻥ ﻤﺭﻴﻀﺎﹰ ﻟﺩﻴﻬﻡ%( 8) ﻤﺭﻀﻰ ﺃﺭﺒﻌﺔﻭﺠﺩ ﻴﻓﻲ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ                
 .ﻭﺍﻟﻭﻗﺎﻴﺔ ﻤﻨﻪ( ﺏ)ﺃﻨﺘﻘﺎل ﻤﺭﺽ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺩ ﺍﻟﻭﺒﺎﺌﻲ ﻤﻥ ﻨﻭﻉ ﻥ ﻜﻴﻔﻴﺔ ﺨﻠﻔﻴﺔ ﻋ
 
 
  
CHAPTER ONE 
INTRODUCTION 
    Hepatitis B (HB) is a serious and common infectious disease of the liver (Chisari 
and Ferrari,1997; Ganem and Schneider, 2001; Hollinger and Liang, 2001; Mahoney and 
Kane, 1999; Kane,1998). Hepatitis B has also been called type B hepatitis, serum 
hepatitis, homologous serum jaundice (Mahoney and Kane, 1999; Robinson, 1995) 
              Hepatitis B is caused by hepatitis B virus (HBV) an enveloped virus containing a 
partially double stranded, circular DNA genome, and classified within the family 
Hepadnaviridae (Chisari and Ferrari, 1997; Mahoney and Kane, 1999; Robinson, 1994; 
Robinson, 1995). Of the many viral causes of human hepatitis few are of greater global 
importance than hepatitis B virus (HBV) (Ganem and Schneider, 2001; Hollinger and 
Liang, 2001; Mahoney and Kane, 1999; Robinson, 1995). 
 The severe pathological consequences of persistent HB infections include the 
development of chronic hepatic insufficiency, cirrhosis, and hepatocelluar carcinoma 
(HCC). In addition, HBV carriers can transmit the disease for many years (Chisari and 
Ferrari, 1997; Mahoney and Kane, 1999; Robinson, 1994; Robinson, 1995). 
Globally, HBV causes 60 - 80% of the world’s primary liver cancers. More than 2 
000 million people alive today have been infected with HBV at some time in their lives, 
of these about 350 million remain infected chronically and become carriers of the virus 
(Chisari and Ferrari, 1997; Hollinger and Liang, 2001; Mahoney and Kane, 1999; World 
Health Organization, 2001). Every year there are over 4 million acute clinical cases of 
HBV, and about 25% of carriers, 1 million people a year, die from chronic active 
hepatitis, cirrhosis or primary liver cancer (World Health Organization, 2001) 
 HBV is transmitted through percutaneous or parenteral contact with infected blood, 
Body fluids, and by sexual intercourse (Ganem and Schneider, 2001; Gitlin, 1997; 
Hollinger and Liang, 2001; Mahoney and Kane, 1999). Sexual intercourse with multiple 
partners or with persons who have multiple partners can be dangerous. Hepatitis B is the 
only sexually transmitted infection for which there is a protective vaccine (Mahoney and 
Kane, 1999). The most important mode of HBV transmission globally is perinatal, from 
the mother to her newborn baby (Hollinger and Liang, 2001). Another important mode of 
HBV transmission is from child to child during early life resulting from blood contact 
(Gitlin, 1997). 
 The world can be divided into three areas where the prevalence of chronic HBV 
infection is high (>8%), intermediate (2 – 8%), and low (<2%)  (Mahoney and Kane., 
1999). 
         The lack of convenient culture system for HBV implies the use of molecular 
biology to assess viremia. Amplification of viral nucleic acid by the polymerase chain 
reaction (PCR) provides a highly sensitive and antigen- antibody-independent method to 
detect ongoing viral infection (Choo et a.,1989; Garson et a.,1990; Inchaups et al, 1991; 
Okamoto et a., 1990). PCR is useful in diagnosis of virus infection when viral antigens 
(Ags) or virus specific Antibodies (Abs) can not be detected and when the presence of 
viral nucleic acid may be the only evidence of infection (Bell et al, 1997).Hepatitis B 
DNA is one of the first things that can be detected in the blood stream after initial 
infection. It can be detected as soon as 1 week after infection (Pawlotskey, 2003; Servoss, 
2004). 
            Several studies were published on sero-prevalence of HB in the Sudan (Hymas et 
al,1989; McCarthy et al, 1989; Elshafie, 1992; Khalil et al, 1996; Fahal et al,1997; and 
Suliaman et al,1997). )   
   Objectives: 
              The aim of this study was to: 
       1- To study by ELISA the prevalence of HBsAg and risk factors among: 
                   (a) Blood donors patients. 
                   (b) Multi-transfused patients. 
                   (c) Jaundice patients. 
                   (d) Haemodialysis patients 
      2- To improve laboratory diagnosis of HBV infection in the Sudan  
                 through introduction of polymerase chain reaction (PCR). 
     5- To determine the prevalence of HCV among HBsAg positive patients as co-
infection.  
 
CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Definition: 
 Hepatitis is a systemic disease primarily involving the liver (Jawetz    et al, 1998). 
This infection or inflammation is the response of tissue injuries and show swelling, 
redness, increase in temperature and loss of function (Weir and Steward, 1997). Hepatitis 
literally means any inflammatory lesion of the liver. In practice the term hepatitis is not 
used for local lesions, such as an abscess but only when there is diffuse involvement of 
the liver.  
         Hepatitis may be acute or chronic infection (Soni et al, 1995). Hepatitis viruses 
produce acute inflammation of the liver, resulting in a clinical illness characterized by 
fever, gastrointestinal symptoms such as nausea, vomiting and jaundice (Jawetz et al, 
1998). 
2.2 Infectious agents: 
 Hepatitis can be caused by a variety of organisms and toxins (William et al, 2001). 
Accordingly hepatitis may be classified as infectious and non infectious hepatitis. Non-
infectious is caused by alcohol, toxins and chemicals or by drugs, whereas infectious 
hepatitis is caused by different microbial agents. However, viruses are considered the 
main causative agents of infectious hepatitis (Jawetz et al, 1998).  
 Most cases of acute viral hepatitis seen in children and adult are caused by one of 
the following agents: in viral hepatitis type A, B, C, D, E and G as shown in Table 1 and 
2. Secondary hepatitis due to other viruses includes yellow fever, Marburg virus, and 
Ebola virus. Also acute hepatitis may occur as an unusual complication of infection by a 
number of non-hepatotropic viruses such as Rubella virus, herpes simplex virus, Epistain-
Barr virus and cytomegalovirus virus (Mowat et al, 2001). 
Table 1: Types of viral hepatitis (Albert et al, 1991). 
Agent 
(Hepatitis 
virus) 
Preferred 
terminology Equivalent terminology 
Infectious hepatitis 
Epidemic jaundice Hepatitis A HAV 
Short incubation hepatitis 
Serum or transfusion hepatitis 
Long incubation hepatitis Hepatitis B HBV 
Homologous serum jaundice 
Hepatitis C HCV Parenterally transmitted non- A, Non-B hepatitis 
Hepatitis D HDV Delta hepatitis 
Hepatitis E HEV Enterically transmitted non-A, non-B hepatitis 
 
2.3 Viral hepatitis: 
2.3.1 Hepatitis type A (HAV): 
           It is caused by a picorna virus genus of the hepatovirus (Minor, 1991) with a 
linear, single-stranded, positive-sense RNA genome, with a size of 7.5 kb and is non 
enveloped virus (William et al, 2001). There is no antigenic cross-reactivity with HBV or 
with other hepatitis viruses (Jawetz et al., 1998). Virion RNA acts as mRNA and is 
translated into a polyprotein, which is then cleaved to individual proteins (Murphy et al, 
1999). The virus is transmitted by oro-feacal route, or ingesting contaminated food or 
water(Snydman et al, 1998), and have short incubation period ranging between 20 to 50 
days, therefore the disease is named short incubation viral hepatitis (Hollinger and 
Ticehurst, 1996). Formation-inactivated whole viruses vaccine is available (William et al, 
2001).    
2.3.2 Hepatitis type D (HDV): 
 HDV or "delta agent" is found in nature only as a result of co-infection with HBV 
(William et al, 2001). HDV is a defective virus, which requires HBV to serve as a helper 
virus; it is often associated with severe form of hepatitis in HBs Ag positive patients 
(Jawetz et a., 1998). HDV has a circular, single stranded negative-sense RNA genome 
(William et al, 2001). It is transmitted by blood and blood products (Table 2) and it does 
not appear to be transmitted sexually (William et al, 2001). 
 No loss of activity occurred following treatment with ethylene diaminetetra-acetic 
acid, but partial or complete loss of activity was detected after treatment with alkali, 
thiocyanate, trichloroacetic acid and proteolytic enzyme (Jawetz et al, 1998). Infection 
acquired at the same time with HBV is called co-infection but if acquire at any time after 
HBV infection is called super-infection which is much more severe and becomes chronic 
in as many 80% of cases (Hoofinagle, 1989) 
2.3.3 Hepatitis type E (HEV): 
 Hepatitis type E is caused by a virus that belong to the family Caliciviridae, it has 
been identified as non -A, non B agent. It is different from the other hepatitis virus it is 
transmitted enterically and occurs in epidemic form in developing countries (Jawetz et al, 
1998). It  virion is non enveloped, with icosahedral symmetry. The genome is composed 
of a single molecule of linear positive-sense, single stranded RNA, and it replicate in the 
cytoplasm (Murphy et al, 1999). HEV is a major cause of enterically transmitted, water-
borne hepatitis in developing countries. No antiviral treatment or vaccine is currently 
available (William et al, 2001). 
2.3.4 Hepatitis type G (HGV): 
 Hepatitis type G caused by a new member of the family flaviviridae, transmitted by 
blood and blood products (Karayiannis et al, 1997). It is associated with morbidity and 
mortality among pregnant women. Hepatitis G virus has been isolated but has not been 
well characterized (Jawetz et al, 1998). 
2.3.5 Hepatitis C Virus (HCV). 
           HCV was discovered in 1989 by investigators at Chiron, Inc. Portions of the HCV 
genome were isolated by screening cDNA expression libraries made from RNA and DNA 
from chimpanzees infected with serum from a patient with post-transfusion non-A, non-B 
hepatitis. [Prior to the discovery of HCV, hepatitis following blood transfusion that was 
not caused by hepatitis A or hepatitis B was referred to as non-A, non-B hepatitis]. To 
identify portions of the genome that encoded viral proteins, the libraries were screened 
with antibodies from patients who had non-A, non-B hepatitis. These investigators went 
on to show that the virus they identified was responsible for the vast majority of cases of 
non-A, non-B hepatitis. They called the new virus hepatitis C virus (HCV). Subsequently, 
the complete genomes of various HCV isolates were cloned and sequenced by several 
groups.  
            HCV is a positive, single-stranded RNA virus in the Flaviviridae family. The 
genome is approximately 10,000 nucleotides and encodes a single polyprotein of about 
3,000 amino acids. The polyprotein is processed by host cell and viral proteases into three 
major structural proteins and several non-structural proteins necessary for viral 
replication. Several different genotypes of HCV with slightly different genomic 
sequences have since been identified that correlate with differences in response to 
treatment with interferon alpha (World health organization 2002). 
              Approximately 170,000,000 peoples worldwide are infected with HCV. The 
virus is transmitted primarily by blood and blood products. The majority of infected 
individuals has either received blood transfusion prior to 1990 (when screening of the 
blood supply for HCV was implemented) or has used intravenous drugs. Sexual 
transmission between monogamous couples is rare but HCV infection is more common in 
sexually promiscuous individuals. Perinatal transmission from mother to fetus or infant is 
also relatively low but possible (less than 10%). Many individuals infected with HCV 
have no obvious risk factors. Most of these persons have probably been inadvertently 
exposed to contaminated blood or blood products.      
(http://www.hon.ch/Library/Theme/HepB/ virology.html). 
2.3.6 Hepatitis type B (HBV): 
 HBV is the cause of serum hepatitis (Jawetz et al, 1998) and is a leading cause of 
chronic hepatitis, cirrhosis and hepatocelular carcinoma (HCC) (William et al, 2001). It is 
classified as hepadnavirus, genus orthohepadna virus (Jawetz et a., 1998). HBV virion 
DNA is a relaxed circular, partially duplex species of 3.2 kb, have an envelope (Knipe et 
al, 2001).HBV infection results from parenteral exposure to virus-containing blood or 
blood products or from sexual contact with an infected host    (Table 2). HBV is 
transmitted mainly by blood and known as serum hepatitis or long-incubation hepatitis 
(Hersh et al, 1971), but breast milk does not appear to play a role in transmission 
(Beasley et al, 1975). 
 
Table 2: Characteristics of hepatitis viruses (Jawetz et al, 1998). 
Virus Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E 
Family Picorna-viridae 
Hepadna-
viridae Flaviviridae Unclassified
Calicivirida
e 
Genus Hepatovirus Ortho-hepadanavirus Unnamed Delta virus Unnamed 
Virion 27 nm, icosahedral 
42 nm 
spherical 
30 – 60 nm 
spherical 
35 nm 
spherical 
30 – 32 m 
icosahedral 
Envelope No Yes (HBsAg) Yes Yes (HBsAg) No 
Genome ssRNA dsDNA ssRNA SsRNA ssRNA 
Genome 
size 7.5 kb 3.2 kb 9.5 kb 1.7 kb 7.6 kb 
Stability Heat- and acid-stable Acid-sensitive 
Ether-
sensitive, 
acid-sensitive
Acid-
sensitive Heat-stable 
Trans-
mission Fecal-oral Parenteral Parenteral Parenteral Fecal-oral 
Prevalence High High Moderate Low, regional Regional 
Fulminant 
disease Rare Rare Rare Frequent 
In 
pregnancy 
Chronic 
disease Never Often Often Often Never 
Oncogenic No Yes Yes ? No 
             
     
 Hepatitis G virus has been isolated but has not been characterized enough to be included 
here. 
  
 
 
          Infectious HBV is present in all body fluids of an infected individual, therefore, 
blood, semen, saliva, serve as source of infection (William et al, 2001). Some infected 
patients never recover completely and are called carriers. Treatment is not very effective, 
so prevention is crucial Recombinant vaccines provide protection in 90 – 95% of healthy 
persons; it can give safety to infants, children and adult in three doses (Mulley et al, 
1982). 
 2.4 Structure and biology of hepatitis B virus: 
           The hepatitis B virus, a hepadnavirus, is a 42 nm partially double stranded DNA 
virus, composed of a 27 nm nucleocapsid core (HBcAg), surrounded by an outer 
lipoprotein coat (also called envelope) containing the surface antigen (HBsAg).  
            Three particulate structures are encountered in the sera of the infected people. The 
most predominant form is that of a small spherical particle 22 nm in diameter with a 
second filament form 22 nm in diameter in lesser concentration than the spherical. Both 
consist of an envelope and carry hepatitis B surface antigen (HBsAg) they are not 
infectious by themselves. A third type is a complex spherical large form with a diameter 
of 42 nm it is termed Dane particle and consists of an outer envelope containing (HBsAg) 
and an inner 27 nm nucleocapsid core. 
           The Dane particle is thought to be the complete infectious virus of hepatitis B. The 
inner particle contains hepatitis B core antigen (HBcAg) within which double stranded 
DNA is found with DNA polymerase as well and protein Kinase. In addition hepatitis B 
`e` antigen (HBeAg) is associated with (HBsAg) has `a` variable epitope and different 
subtypes sharing `a` common epitope called a which is linked with two mutually 
exclusive determinant "d" or "γ" and "w" or "r" giving the four main subtypes "adw", 
"ayw", "adr", "aγr". The different subtypes are useful as epidemiological markers of HBV 
and are not markers of virulence or chronicity (Bancroft et a, 1972; Mosely et a, 1972). 
HBsAg is transcribed to produce three mRNAs; S, M and L. Each mRNA produces a 
protein contains the major S protein. The M mRNA and the L mRNA produce (pre S1+S) 
and (pre S2+S) respectively. HBcAg unlike HBsAg is found mostly in the nucleus of the 
infected hepatocyte and generally is not found to be circulating. It must be extracelular at 
some time during infection to be detected by the immune system. 
 HBeAg exists in a soluble, non-particulate form in contrast to HBsAg and HBcAg. 
Since the Dane particle is thought to be the infectious virion, the presence of e antigen is 
a marker of the complete virus and its infectivity. The persistence of HBeAg beyond 8 
weeks after the acute hepatitis B may be indicative for the occurrence of chronic hepatitis 
with more aggressive hepatic lesion than the presence of anti HBe. HbeAg usually found 
in sera is reactive for HBsAg ( Neurath and Kent, 1988; Lutwick, 1991). 
2.5 Classification of HBV: 
            The family of hepadnaviruses (Hepadnaviridae) comprises members recovered 
from a variety of animal species, including the woodchuck hepatitis virus (WHV), the 
ground squirrel hepatitis virus (GSHV), and the duck HBV. Common features of all these 
viruses are enveloped virions containing 3 to 3.3 kb of relaxed circular, partially duplex 
DNA and virion-associated DNA- dependent polymerases that can repair the gap in the 
virion DNA template and have reverse transcriptase activities. Hepadnaviruses show 
narrow host ranges, growing only in species close to the natural host, like gibbons, 
African green monkeys, rhesus monkeys, and wooly monkeys (Hollinger and Liang, 
2001; Robinson, 1994; Robinson, 1995). 
 Mammalian hepadnaviruses fail to propagate in cell culture (Mahoney and Kane, 
1999; Robinson, 1994; Robinson, 1995). Intracellular HBV is non-cytopathic and causes 
little or no damage to the cell (Chisari and Ferrari, 1997; Ganem and Schneider, 2001; 
Hollinger and Liang, 2001; Mahoney and Kane, 1999). 
2.6 The hepatitis B virus Replication: 
 The HBV virion binds to a receptor at the surface of the hepatocyte (Ganem and 
Schneider, 2001). Viral nucleocapsids enter the cell and reach the nucleus, where the viral 
genome is delivered (Chisari et al, 1997; Ganem and Schneider, 2001; Mahoney and 
Kane, 1999). 
 In the nucleus, second-strand DNA synthesis is completed and the gaps in both 
strands are repaired to yield a covalently closed circular (ccc) supercoiled DNA molecule 
that serves as a template for transcription of four viral RNAs that are 3.5, 2.4, 2.1 and 0.7 
kb long (Chisari et al, 1997; Ganem and Schneider, 2001; Mahoney and Kane, 1999; 
Robinson, 1995). 
 These transcripts are polyadenylated and transported to the cytoplasm, where they 
are translated into the viral nucleocapsid and precore antigen (C, pre-C), polymerase (P), 
envelope L (large), M (medium, S (small), and transcriptional transactivating proteins (X) 
(Chisari et al, 1997; Ganem and Schneider, 2001; Mahoney and Kane, 1999; Robinson, 
1995). The envelope proteins insert themselves as integral membrane proteins into the 
lipid membrane of the endoplasmic reticulum (ER). 
 The 3.5 kb species, spanning the entire genome and termed pregenomic RNA 
(pgRNA), is packaged together with HBV polymerase and a protein kinase into core 
particles where it serves as a template for reverse transcription of negative-strand DNA. 
The RNA to DNA conversion takes place inside the particles. The new, mature, viral 
nucleocapsids can then follow two different intracellular pathways, one of which leads to 
the formation and secretion of new virions, whereas the other leads to amplification of the 
viral genome inside the cell nucleus(Ganem and Schneider, 2001; Mahoney and Kane, 
1999). 
 The precore polypeptide is transported into the ER lumen, where its amino- and 
carboxy-termini are trimmed and the resultant protein is secreted as precore antigen. The 
X protein contributes to the efficiency of HBV replication by interacting with different 
transcription factors, and is capable of stimulating both cell proliferation and cell death 
(Ganem and Schneider, 2001; Mahoney and Kane, 1999).  
2.7 Genome Structure and Proteins of HBV: 
  HBV virion DNA is a relaxed circular, partially duplex molecule of 3.2 kb, whose 
circularity is maintained by 5'cohesive ends (Hollinger and Liang, 2001; Robinson, 1995 
). The positions of the 5' ends of both strands map to the regions of short (11 nucleotides) 
direct repeats (DRs) in viral DNA. The 5' end of the minus strand DNA maps within the 
repeat termed DR, while plus strand DNA begins with DR2. These repeats are involved 
in priming the synthesis of their respective DNA strands (Chisari et al, 1997).  
2.8 Pathogenesis and pathology: 
 Although the biological incubation period of HBV is short, the clinical incubation 
period is long. During the clinical incubation of HBV, the infected individual despite 
being HBsAg positive, remains well without biochemical or histologic evidence of liver 
disease. This observation suggests that the HBV by itself is not cytopathogenic for the 
hepatocyte (Lutwick, 1991). HBV infection contracted early in life may lead to chronic 
hepatitis, then to cirrhosis, and finally to HCC, usually after a period of 30 to 50 years. 
Once infected with HBV, males are more likely to remain persistently infected than 
women, who are more likely to be infected transiently and to develop anti-HBs.  
Damage to the liver cells is attributed to the host immunologic response due to 
viral antigens. The core and surface antigens induce both B and T cells. The damage 
could result from both antibody dependent cytotoxicity and T cell cytotoxic action but 
action of cytotoxic T, cells specific for HBcAg is the major factor (Dudley et al, 1972). It 
is possible that in man HBV is not carcinogenic by a direct viral mechanism. Instead, the 
role of HBV may be to cause chronic liver cell damage with associated host responses of 
inflammation and liver regeneration that continues for many years. This pathological 
process, especially when leading to cirrhosis, may be carcinogenic without involving a 
direct oncogenic action of the virus. 
           The expression of HBV proteins and the release of virions precedes biochemical 
evidence of liver disease. Moreover, large quantities of surface antigen can persist in liver 
cells of many apparently healthy persons who are carriers. HBV is therefore not directly 
cytopathic (Chisari and Ferrari, 1997).  
2.9 Endemicity of hepatitis B virus: 
  There are no seasonal preferences for primary HBV infections (Hollinger and 
Liang, 2001; Robinson, 1994).  
 Hepatitis B is highly endemic in all of Africa, some parts of South America, 
Alaska, northern Canada and parts of Greenland, Eastern Europe, the eastern 
Mediterranean area, Southeast Asia, China and the Pacific Islands, except Australia, New 
Zealand and Japan. In most of these areas, 5 to 15% of the population are chronically 
infected carriers of HBV, and in some areas may also carry HDV, which may lead to 
severe liver damage (Mahoney and Kane, 1999). 
 2.10 Epidemiology of hepatitis B virus: 
 The hepatitis B virus is a ubiquitous virus with a global distribution (Hollinger and 
Liang, 2001; Robinson, 1994). Hepatitis B is one of the 4 world's most common and 
serious infectious diseases. It is estimated that more than one third of the world's 
population has been infected with the hepatitis B virus. About 5% of the populations are 
chronic carriers of HBV, and nearly 25% of all carriers develop serious liver diseases 
such as chronic hepatitis, cirrhosis, and primary hepatocullular carcinoma. HBV infection 
causes more than one million deaths every year (Hollinger and Liang, 2001; Mahoney 
and Kane, 1999; Robinson, 1994). 
 The HBsAg carrier rate varies from 0.1 to 20% in different populations around the 
word. The incidence of the HBsAg carrier state in populations is related most importantly 
to the incidence and age of primary infection (Mahoney and Kane, 1999).  
 In low-risk areas of the world, the highest incidence of the disease is seen in 
teenagers and young adults. Deposit the low incidence of disease seen in the general 
population, certain groups who are sexually promiscuous or who have frequent contact 
with blood or blood products have a high rate of HBV infection. Nevertheless, the 
availability of an effective vaccine, optimized blood donor screening, and better 
sterilization procedures for blood derivatives have lowered substantially the infection risk 
(Hollinger and Liang, 2001). 
 In endemic areas of Africa and Asia, different epidemiological patterns are seen. In 
these regions, most infections occur in infants and children as a result of maternal-
neonatal transmission or close childhood contact, although percutaneous exposure with 
contaminated needles or following unsafe injections is always a possibility in these 
countries (Hollinger and Liang, 2001; Mahoney and Kane, 1999).   
 The chronic liver disease and HCC associated with HBV infections are among the 
most important human health problems in high-prevalence regions (World Health 
Organization, 2002). 
2.11 Transmission: 
Currently, there are four recognized modes of transmission From mother to child at 
birth (perinatal), by contact with an infected person (horizontal), by sexual contact and by 
parenteral (blood-to-blood) exposure to blood or other infected fluids (Hollinger and 
Liang, 2001; World Health Organization, 2002). 
There is considerable variation between areas, countries and continents as to the 
age at which most transmission takes place. There can be carriers with or without 
hepatitis (Robinson, 1995). There is no convincing evidence that airborne infections 
occur and faeces are not a source of infection, since the virus is inactivated by enzymes of 
the intestinal mucosa or derived from the bacterial flora. HBV is not transmitted by 
contaminated food or water, insects or other vectors (Hollinger and Liang, 2001; 
Robinson, 1995). 
HBsAg has been found in all body secretions and excretions. However, only blood, 
vaginal and menstrual fluids, and semen have been shown to be infectious (Hollinger and 
Liang, 2001; Mahoney and Kane, 1999; Robinson, 1994; Robinson, 1995). 
Transmission occurs by percutaneous and permucosal exposure to infective body 
fluids. Percutaneous exposures that have resulted in HBV transmission include 
transfusion of unscreened blood or blood products, sharing unsterilized injection needles 
for intra venous drug use, haemodialysis, acupuncture, tattooing and injuries from 
contaminated sharp instruments sustained by hospital personnel. Sexual and perinatal 
HBV transmission usually result from mucous membrane exposures to infectious blood 
and body fluids. Perinatal transmission is common in hyper endemic areas of Southeast 
Asia and the Far East, especially when HBsAg carrier mothers are also HBeAg positive 
(Hollinger and Liang, 2001, Mahoney and Kane, 1999, Robinson, 1995).  
Infection may also be transmitted between household contacts and between sexual 
partners, either homosexual or heterosexual, and in oddler-aged children in groups with 
high HBsAg carrier rates (Hollinger and Liang, 2001; Mahoney and Kane, 1999). 
HBV is stable on environmental surfaces for at least 7 days, and indirect 
inoculation of HBV can occur via inanimate objects like toothbrushes, bay bottles, toys, 
razors, eating utensils, hospital equipment and other objects by contact with mucous 
membranes or open skin breaks. Infectious HBV can be present in blood without 
detectable HBsAg, so that the failure to detect antigen does not exclude the presence of 
infectious virus (Robinson, 1994). 
The source of infection cannot be identified in about 35% of cases. 
The natural reservoir for HBV is man, closely related hepadnaviruses have been found in 
woodchucks and ducks, but they are not infectious for humans (Ganem and Schneider, 
2001). The reuse of the same, unsterilized needle and syringe for vaccination of many 
different children accounts for many unnecessary HBV infections. (Robinson, 1994) 
2.11.1The role of non-human primates in the transmission of HBV: 
 The only non-human primates that can develop productive HBV infection are the 
great apes (e.g. chimpanzees and gorillas), Chimpanzees have served as the model for the 
study of HBV infection for over 20 years (Holliger and Liang, 2001) though chimpanzees 
may be infected in nature, there is no evidence that they are important sources for 
transmission for human infection, because transmission from infected individuals requires 
specific patterns and intimate contact (Robinson, 1995). 
Gibbons are susceptible to HBV and have been infected successfully 
experimentally and also naturally by contact in captivity (Thornton et al, 2001).  
2.12 Hepatitis B virus DNA and hepatocellular carcinoma: 
 More than 85% of hepatocullular tumours examined harbor integrated HBV DNA, 
often multiple copies per cell. The viral DNA integrants are usually highly rearranged, 
with deletions, inversions, and sequence reiterations all commonly observed. Most of 
these rearrangements ablate viral gene expression, but the integrations alter the host DNA 
(Ganem and Schneider, 2001; Robinson, 1994; Zuckerman, 1996). 
 There is no similarity in the pattern of integration between different tumours, and 
variation is seen both in the integration site(s) and in the number of copies or partial 
copies of the viral genome. The molecular mechanisms by which hepadnaviruses 
predispose to malignancy are still unknown (Zuckerman, 1996). 
2.13 HBV mutants: 
 Naturally occurring envelope, precore, core, and polymerase variants have been 
described (Gitlin, 1997; Hollinger and Liang, 2001; Mahoney and Kane, 1999). Envelope 
antigenic variants may have a selective advantage over wild type under immune selection 
pressure, as observed in some cases after hepatitis B IG (HBIG) treatment of HBV 
vaccination, an epidemiological shift has not been observed yet (World Health 
Organization, 2002). A number of precore mutations preventing HBeAg synthesis have 
been identified in HBeAg negative carriers. The most frequent variant has a G to A point 
mutation at nucleotide 83. 
 HBV is far more heterogenous than is generally thought. The HBV genome seems 
not to be characterized by a single representative genomic molecule, but by a pool of 
genomes which differ both in structure and function. The public health importance of 
mutant hepatitis B viruses is currently under debate. Further studies and a strict 
surveillance to detect the emergence of these viruses are crucial for a correct evaluation of 
the effectiveness of current immunization strategies (Mahoney and Kane, 1999 
;Zuckerman, 1996; Zuckerman, 2000). 
2.14 Antigenicity of hepatitis B virus: 
 All three coat proteins of HBV contain HBsAg, which is highly immunogenic and 
induces anti-HBs (humoral immunity). Structural viral proteins induce specific T-
lymphocytes, capable of eliminating HBV-infected cells (cytotoxic T-cells; cellular 
immunity), (Chisari and Ferrari, 1997; Hollinger and Liang, 2001). HBsAg is 
heterogeneous antigenically, with a common antigen designated a, and two pairs of 
mutually exclusive antigens, d, and y, and w (including several sub determinants) and r, 
resulting in 4 major subtype adw, ayw, adr and ayr. (Mahoney and Kane, 1999; Robinson, 
1994; Robinson, 1995). 
The core antigen shares its sequences with the e antigen (HBeAg), identified as a 
soluble antigen, but no cross reactivity between the two proteins is observed (Robinson, 
1994; Robinson, 1995). 
Viral oligopeptides of 8-15 amino acids are loaded on host cell MHC-class I 
molecules and are transported to the surface of the cell. HBV-specific T-lymphocytes can 
then detect infected cells and destroy them. This cell deletion triggered by inflammation 
cells may result in acute hepatitis. When the infection is self limited, immunity results. If 
HBV is not eliminated, a delicate balance between viral replication and immunodefence 
prevails which may lead to chronic hepatitis and liver cirrhosis. In chronically infected 
cells the HBV DNA may integrate into the host cell DNA. As a long term consequence, 
integration may lead to hepatocellular carcinoma (Hollinger and Liang, 2001; Mahoney 
and Kane, 1999; Zuckerman, 1996). 
2.15 Stability of hepatitis B virus: 
The stability of HBV does not always coincide with that of HBsAg (Hollinger and 
Liang, 2001). Exposure to ether, acid (pH 2.4 for at least 6 h), and heat (98ºC for 1min; 
60ºfor 10 h) does not destroy immunogenicity or antigenicity. However, inactivation may 
be incomplete under these conditions if the concentration of virus is excessively high. 
Antigenicity and probably infectivty are destroyed after exposure of HBsAg to 0.25% 
sodium hypochlorite for 3min (Hollinger and Liang, 2001). 
Infectivity is lost after autoclaving at 121ºC for 20 min or dry heat treatment at 
160ºC for 1 h (Hollinger and Liang, 2001; Robinson, 1995). 
HBV is inactivated by exposure to sodium hypochlorite (500 mg free chlorine per 
litter) for 10 min, 2% aqueous glutaraldehyde at room temperature for 5 min, heat 
treatment at 98ºC for 2 min, sporicidin (pH 7.9), formaldehyde at 18.5 g/l (5% formalin in 
water), 70% isopropyl alcohol, 80% ethyl alcohol at 11ºC for 2 min, wescodyne diluted 
1:213, or combined β-propriolactone and UV irradiation (Hollinger and Liang, 2001; 
World Health Organization, 1998). HBV retains infectivity when stored at 30ºC to 32ºC 
for at least 6 months and when frozen at-15ºC for 15 years. HBV present in blood can 
withstand drying on a surface for at least a week (Hollinger and Liang, 2001; Robinson, 
1995).                                                                                                                                                                
 2.16 Persistent of Hepatitis B Infection :   
            Persistent or chronic HBV infection is among the most common persistent viral 
infections in humans. More than 350 million people in the world today are estimated to 
be persistently infected with HBV. A large fraction of these are in eastern Asia and sub-
Saharan Africa, where the associated complications of chronic liver disease and liver 
cancer are the most important health problems (Robinson, 1995). 
A small number of long-established chronic carriers apparently terminate their 
active infection and become HBsAg-negative (about 2% per year). Survivors of fulminant 
hepatitis rarely become infected persistently, and HBsAg carriers frequently have no 
history of recognized acute hepatitis (World Health Organization, 2002). 
The infecting dose of virus and the age of the person infected are important factors 
that correlate with the severity of actual or chronic hepatitis B (Mahoney and Kane, 1999; 
Robinson, 1995). 
Primary HBV infection may be associated with little or no liver disease or with 
acute hepatitis of severity ranging from mild to fulminant (Robinson, 1995). HBV 
infection is transient in about 90% of adults and 10% of newborn, and persistent in the 
remainder (Mahoney and Kane, 1999). 
2.17 Clinical features: 
The clinical incubation period of HBV varies between 2-6 months with a mean of 
approximately 3 months. The onset is insidious. The early symptoms of acute stage 
include fatigue and malaise with or without less common serum sickness type illness. 
Fever is less common. Acute hepatic manifestation of HBV ranges from asymptotic to 
severe icteric disease.  HBV  infection is an iceteric in 50% of cases or  more. The 
jaundice when present is preceded by nausea, vomiting, anorexia and mild fever. These 
symptoms and the jaundice fade in the second or third weeks of illness. A small 
percentage (0.2 – 0.5%) of icteric hepatitis B cases may develop acute fulminate hepatitis 
which carries a high fatality rate (70 – 90%). A significant subacute hepatic necrosis may 
develop to post-necrotic cirrhosis (Lutwick, 1991). HBV infection may shows extra-
hepatic manifestations including skin rash, polyarteritis and glomerulonephritis. 
 Although most cases of acute HBV recover within 4 months, the typical HBV 
infection is characterized by the development of persistent surface antigenaemia 
(Nordenfelt, 1990; Lutwick, 1991). 
 The determinant factors for developing persistent infection is not yet clear. 
Epidemiological studies showed that age, sex and immunologic status of the infected 
person are important factors (Nordenfelt et al, 1982; Hoofinagle and Alter, 1984; 
Peutherer, 1992). Neonates exposed to HBV infection at the time of birth and children 
less than 5 years are more amenable to develop persistent infection than adults. Women 
are less predisposed to develop into chronic asymptotic carriers than men. Finally 
immuocompromised individuals are more amenable to develop persistent infection. In 
prospective studies conducted in dialysis units it was found that the renal dialysis patients 
develop into chronic carriers more than controls. Down's syndrome also makes the 
individuals more susceptible to the persistent infection (Nordenfelt  et al, 1982; 
Hoofinagle and Alter, 1984). 
2.17.1 Clinical features of acute hepatitis B infection : 
The acute form of the disease often resolves spontaneously after a 4-8 week illness. 
Most patients recover without significant consequences and without recurrence. However, 
a favorable prognosis is not certain, especially in the elderly who can develop 
fulminating, fatal cases of acute hepatic necrosis. Young children rarely develop acute 
clinical disease, but many of those infected before the age of seven will become chronic 
carriers (Chisari and Ferrari, 1997; Hollinger and Liang, 2001; Mahoney and Kane, 1999; 
Robinson, 1994; Robinson, 1995). 
2.17.2 Clinical features of chronic hepatitis B : 
Although most adult patients recover completely from an acute episode of hepatitis 
B, in a significant proportion, 5 to 10%, the virus persists in the body. This figure is much 
higher in children 70 to 90% of infants infected in their first few years of life become 
chronic carriers of HBV (Mahoney and Kane., 1999; Robinson., 1995). 
Chronic hepatitis can cause serious destructive disease of the liver and it contribute 
greatly to the worldwide burden of the disease (Mahoney and Kane, 1999). Chronic 
hepatitis generally develops over many years during which individual patients will pass 
through a number of disease states (World Health Organization, 2002) 
Chronic hepatitis B is a prolonged ( > 6 months) infection with persistent serum 
levels of HBsAg and lgG anti-HBsAg antibody response. HBV DNA and HBeAg are 
often detectable at high concentrations, but may disappear if viral replication ceases or if 
mutations occur that prevent the synthesis of the viral precore protein precursor of 
HBeAg. The associated inflammatory liver disease is variable in severity. It is always 
much milder than in acute hepatitis B, but it can be last for decades and proceed to 
cirrhosis, and it is associated with a 100-fold increase in the risk of developing a 
hepatocellular carcinoma (Hollinger and Liang, 2001; Robinson, 1995) 
2.18 HBV and hepatocellular carcinoma (HCC): 
A number of HBV patients with chronic hepatitis will develop hepatocellular 
carcinoma. Persons at increased risk of developing HCC include adult male and chronic 
hepatitis B patients with cirrhosis who contracted hepatitis B in early childhood. Only 
about 5% of patients with cirrhosis develop HCC patients have underlying cirrhosis 
(Mahoney and Kane, 1999; Hollinger and Liang, 2001; Robinson, 1995). 
The incidence of HCC varies with geography, race, age, and sex. HCC is 
responsible for 90% of the primary malignant tumours of the liver observed in adults. 
Worldwide, it is the seventh most frequent cancer in males and ninth most common in 
females. Liver cancer is the causes of more than 500 000 deaths annually through the 
world, with a male: female ratio of 4:1. The frequency of HCC follows the same general 
geographic distribution patterns as that of persistent HBV infection. The age distribution 
of patients with clinically recognized tumours suggest that these tumours appear after a 
mean duration of about 35 years of HBV infection (Hollinger and Liang, 2001; Robinson, 
1995). 
HBV causes 60-80% of the world’s primary liver cancer, and primary liver cancer 
is one of the three most common causes of cancer deaths in males in east and south-east 
Asia, the pacific basin, and sub-Saharan Africa. Primary liver cancer is the eight most 
common cancers in the world, up to 80% of liver cancers are due to HBV (Robinson, 
1995). When HCC presents clinically, the disease is fatal (World Health Organization, 
2002). 
2.19 Co-infection or super infection with HDV:  
Hepatitis Delta virus (HDV) is a defective virus that is only infectious in the 
presence of active HBV infection. HDV infection occurs as either co-infection with HBV 
or super infection of an HBV carrier. Co-infection usually resolves. Super infection, 
however, causes frequently chronic HDV infection and chronic active hepatitis. Both 
types of infections may causes fulminant hepatitis and routes of transmission are similar 
to those of HBV (Centers for Disease control and prevention, 1991; Robinson, 1995). 
Preventing acute and chronic HBV infection of susceptible persons by vaccination 
will also prevent HDV infection (Centers for Disease control and prevention, 1991; 
Mahoney and Kane, 1999). 
2.20 Immunological response to HBV infection: 
 The humoral immune response to HBV becomes detectable some weeks after the 
appearance of HBsAg. The first antibody detected is anti-HBc antibody. Although anti-
HBsAg may be produced during the surface antigenemic period it is usually undetectable. 
Anti-HBc antibody continues to rise during acute infection to high titers in early 
convalescence. These antibodies are initially IgM and then IgG. HBeAg becomes 
detectable late in the incubation period and remains detectable for a variable time during 
acute disease. After HBeAg is cleared from the serum, anti-HBe becomes detectable 
either immediately or within several weeks. Following HBsAg is present but high levels 
of anti-HBc (including IgM anti-HBc) are found (Lutwick, 1991). 
 In some cases anti-HBs antibody titers continue to rise following recovery from 
acute hepatitis B for 6-12 months and in contrast to anti-HBc, the individuals with the 
highest titers of anti-HBs exhibit the shortest periods of HBsAg positivity. In 
convalescence the three antibodies can be found for sometime (Lutwick, 1991; Jawetz et 
al, 1998). 
 Anti-HBe was first. Anti-HBs is protective and usually signifies immunity against 
future infection. Anti-HBc persists for years after the acute infection and it's not 
protective experimentally. The persistence of anti-HBc  
antibody titers at high levels indicates continuing production of HBcAg in patients who 
do not clear HBsAg. HBeAg may also continue to circulate in these patients. HBeAg may 
eventually be replaced by anti-HBe in chronic carriers some chronic HBsAg carriers 
seem to have a specific B lymphocyte defect of anti-HBs production and some defects in 
regulatory T cell (Lutwick, 1991; Jawetz et al, 1998). 
2.21 Prevalence of hepatitis B virus: 
 HBV occurs worldwide (Figure1) (Mahoney and Kane., 1999; Robinson., 1995). 
The highest rates of HBsAg carrier rates are found in developing countries with primitive 
or limited medical facilities (Mahoney and Kane, 1999). In areas of Africa and Asia, 
widespread infection may occur in infancy and childhood. The overall HBsAg carrier 
rates may be 10 to 15%. 
 In North America infection is most common in young adults. In the USA and 
Canada, serological evidence of previous infection varies depending on age and 
socioeconomic class. Overall, 5% of the adult USA population has anti-HBc, and 0.5% 
are HBsAg positive (World Health Organization, 2002).              
In developed countries, exposure to HBV may be common in certain high risk 
groups. Adults infected with HBV usually acquire acute hepatitis B and recover, but 5 to 
10% develop the chronic carrier state.  
 
Fig. 1: Geographic distribution of Hepatitis B prevalence (Centers for disease Control 
and Prevention).   
 
Infected children rarely develop acute disease, but 25 to 90% become chronic 
carriers. About 25% of carriers will die from cirrhosis or primary liver cancer as adults 
(Centers for Disease control and prevention, 1991; 1991; Mahoney and Kane, 1999).  
 In the past, recipients of blood and blood products were at high risk (for HBV 
infection), over the last 25 years, testing blood donations for HBsAg has become a 
universal requirement. Testing procedures have made major progress in sensitivity in the 
last 15 – 20 years. However 19% of countries reported that they were not testing all blood 
donations for HBsAg  (WHO Global Database on Blood Safety, unpublished data). In the 
many countries where pre-transfusion screening of blood donations for HBsAg is carried 
out systematically, the residual risk of HBV transmission is minimal. Moreover, plasma 
derived medicinal products (including anti-haemophilic factors) undergo additional viral 
inactivation and removal procedures resulting in greatly reduced or no transmission of 
HBV by these products. 
 However, the risk is still present in many developing countries. Contaminated and 
inadequately sterilized syringes and needles have resulted in outbreaks of hepatitis B 
among patients in clinics and physicians' offices. Occasionally, outbreaks have been 
traced to tattoo priors and acupuncturists. Rarely, transmission to patients from HBsAg 
positive health care workers has been documented (Viral Hepatitis Prevention Board, 
1998). 
2.21.1 Hepatitis B in the Sudan: 
              Now, there are few data regarding the presence of HBV was widely prevalent in 
the Sudan. Hyams et al. (1989) reported seropositivity of 18.7% for HBsAg and 63.9% 
for HBV markers from two villages of Gezira region. A sero-survey for HBV antibodies 
among sexually active heterosexuals in Port Sudan conducted by McCarthy et al. (1989) 
showed HBsAg in 14% of the entire study population and anti-HBs, Anti-HBc in 
additional 49% and 27% of sera respectively.  
           Hyams et al. (1991) reported a prevalence of 10% HBV in Sudanese children in 
one of the public pediatric clinics. A study from Gezira area in blood donors and 
technical staff showed a prevalence of 17.3% and 12% in each group respectively (El 
Shaffie, 1992). McCarthy et al. (1994) in a survey for HBV and HIV in Juba found 
HBsAg in 20% of the population, anti-HBc in 67% and HCV in 3% only. In a study on 
gastrointestinal tract cancer, HBsAg was detected in 18% of the patients and 12% of the 
normal subjects (Fahal et al. 1995). 
             In a survey on hepatitis A and B virus in subjects consisted of 25 control 
hospitalized patients, 21 volunteer blood donors, 23 patients with hepatosplenic 
schistosomiasis, 13 patients with liver cirrhosis and 6 patients with hepatocellular 
carcinoma, HBsAg was positive in 4, 24, 22, 31 and 67% respectively, and the antibodies 
for HBV in undiluted sera were 60, 57, 65, 77 and 83% respectively (Khalil et al, 1996). 
Suliaman et al. (1997) found a prevalence of 27.7% of HBV among haemodialysis 
patients from Khartoum Kidney Dialysis Center.  
            Some of these studies suggested that the principal mode of transmission in the 
Sudan is the parenteral mode of transmission (Khalil, 1996; Hyams et al, 1989; McCarty 
et al, 1989; Suliaman   et al, (1997).  
            The prevalence of HBV among male Sudanese screened for employment in Gulf 
countries was 10% ( Elkhidir,personal communication).   
2.22 Vaccines of HBV: 
             Hepatitis B is a vaccine-preventable disease, but although global control of 
hepatitis B is achievable, it has not been attained yet (Centers for Disease Control and 
Prevention, 1998; VanDamme et al, 1997). In fact, a large pool of carriers and the burden 
of their disease remains, so that efforts must necessarily continue to treat the various 
stages of disease (World Health Organization, 2002). 
 HB vaccine is the first and currently the only vaccine against a major human 
cancer. Vaccination is the most effective tool in preventing the transmission of HBV and 
HDV. Vaccines are composed of the surface antigen of HBV (HBsAg), and are produced 
by two different methods plasma derived or recombinant DNA. When administered 
properly, hepatitis B vaccine induces protection in about 95% of recipients (Centers for 
Disease Control and Prevention, 1998). 
 Systematic hepatitis B vaccination of newborns renders the screening of pregnant 
women for HBsAg status before delivery superfluous (Mahoney and Lane, 1999). The 
primary objective of hepatitis B immunization is to prevent chronic HBV infections 
which result in chronic liver disease later in life. By preventing chronic HBV infections, 
the major reservoir for transmission of new infections is also reduced (World Health 
Organization, 2002). 
2.23 Diagnosis of HBV: 
Diagnosis of hepatitis is confirmed by demonstration in sera of specific antigens 
and/or antibodies. Three clinically useful antigen-antibody systems have been identified 
for hepatitis B. Hepatitis B surface antigen (HBsAg) and antibody to HBsAg   (anti-HBs). 
Antibody (anti-HBc IgM and anti-HBc IgG) to hepatitis B core antigen (HBcAg). 
Hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe) . 
2.24 Immunodiagnostic tests:  
Enzyme immunoassays referred to as enzyme linked immuno-sorbent assay 
(ELISA), have revolutionized diagnostic virology. Assay can be designed to detect viral 
antigen (A) or antibodies (Abs). The exquisite sensitivity of the method enables less than 
1 ng of viral Ag per ml to be detected. A wide variety of different assays procedures are 
used including: direct, indirect, sandwich and competitive assay. 
ELISA was first utilized in hepatitis research to detect HBs-Ag and anti-HBs Ab 
using sandwich method principle employed in solid-phase radioimmunoassay (RIA) 
procedure that predated ELISA. In this technique the enzyme labeled Ab is substituted for 
radionuclide labeled preparation, its presence being reflected by hydrolysis of the 
subsequent added enzyme substrate. The colour produced can be quantitated 
spectrophotomerically (Feuch et al, 1995). 
HBsAg can be detected in the serum from several weeks before onset of symptoms 
to months after onset. HBsAg is present in serum during acute infections and persists in 
chronic infections. The presence of HBsAg indicates that the person is potential 
infectious (Hollinger and Liane, 2001; Mahoney and Kane, 1999; Robinson, 1995). 
Very early in the incubation period, pre-S1 and pre-S2 antigens are present. They 
are never detected in the absence of HBsAg. Hepatitis B virions, HBV DNA, DNA 
polymerase, and HBsAg are then also detected. The presence of HBeAg is associated 
with relatively high infectivity and severity of disease (Hollinger and Liane, 2001; 
Robinson, 1995). 
Anti-HBc is the first antibody to appear. Demonstration of anti-HBc in serum 
indicates HBV infection, current or past. IgM anti-HBc is present in high titer during 
acute infection and usually disappears within 6 months. Although it can persist in some 
cases of chronic hepatitis. This test may therefore reliably diagnose acute HBV infection. 
IgG anti-HBc generally remains detectable for a lifetime. Anti-HBe appears after anti-
HBc and its presence correlates to a decreased infectivity. Anti-HBe replaces HBeAg in 
the resolution of the disease. Anti-HBs replace HBsAg as the acute HBV infection is 
resolving. Anti-HBs generally persists for a lifetime in over 80% of patients and indicates 
immunity (Hollinger and Liane, 2001; Mahoney and Kane, 1999; Robinson, 1995). 
Acute hepatitis patients who maintain a constant serum HBsAg concentration, or 
whose serum HBeAg persists 8 to 10 weeks after symptoms have resolved, are likely to 
become carriers and at risk of developing chronic liver disease. Complication in the 
diagnosis of hepatitis B is the rare identification of cases in which viral mutations change 
the antigens so they are not detectable (Hollinger and Liane, 2001). 
Hepatitis B DNA is one of the first things that can be detected in the blood stream 
after initial infection. It can be detected as soon as 1 week after infection using sensitive 
tests. It is believed that the level of HBV DNA may indicate how fast the virus is 
replicating. The test for HBV DNA is performed using PCR technique 
(http://www.hon.ch/Library/Theme/HepB/ virology.html). 
Immunofluorescence studies, in situ hybridization, immunohisto-chemistry, and 
thin-section electron microscopy are used to examine pathological specimens for the 
presence of HBV-associated antigens or particles, providing information about the 
relationship between HBV DNA replication and HBV gene expression within the 
hepatocyte, HBsAg localizes in the cytoplasm, and HBcAg is seen in the nucleus and/or 
the cytoplasm. Detection of complete virions in the liver is uncommon   (Hollinger and 
Liane, 2001). 
DNA hybridization techniques and PCR assays have shown that almost all 
HBsAg/HBeAg-positive patients have detectable HBV DNA in their serum, whereas only 
about 65% of the HBsAg/anti-HBe reactive patients are positive. All patients who recover 
from acute hepatitis B are negative for HBV DNA. Some patients infected chronically 
who have lost their HBsAg remain HBV DNA positive (Hollinger and Liane, 2001; 
Robinson, 1995) 
 
2.24.1 HBV serological markers in hepatitis patients: 
The three standard blood tests for hepatitis B can determine if a person is currently 
infected with HBV, has recovered, is a chronic carrier, or is susceptible to HBV infection 
(Hollinger and Liane, 2001; Mahoney and Kane, 1999; Robinson, 1995). 
          During HBV infection, the serological markers vary depending on whether the 
infection is acute or chronic (Gitlin, 1997; Mahoney and Kane, 1999; Robinson, 1995). 
2.25 Immunochromatography technique (ICT): 
The HBV ICT or one step test device (serum/plasma) is a rapid immunoassay for 
the qualitative detection the presence of antigens to HBV (Choo., 1989). ICT are modeled 
after the home pregnancy test used by women in many countries. They differ from usual 
systems for measuring antigen-antibody reactions in that the specimen from the human 
subject is made to flow through a filter after which it is immobilized in a membrane at the 
a site where antigen (or antibody) in the specimen comes into contact with the test 
antibody (or antigen) already present in the membrane. All controls are included in the 
membrane as well, and results are seen as colored bands or lines, as one of the test 
reagents is conjugated to colloidal gold or chromogenic substance (Murphy et al, 1999). 
2.26 Polymerase chain reaction (PCR): 
The polymerase chain reaction (PCR) is an in vitro method for enzymatic synthesis 
of specific DNA sequence using two oligonculeotide primers, usually of about 20 
residues, that hybridize to opposite strands and flank the region of interest of the target 
DNA, the primer pairs are sometimes referred to as forward and reverse primer. 
Computer programmes are used for the design of optimal primer sets and to predict the 
parameters (time/temp.) for the reactions. Depending on the degree of conservation of the 
putative target sequence, primers may be chosen to be strain, genus or family specific 
(Bukh et al, 1993). 
PCR is useful in diagnosis of virus infection when viral antigens (Ags) or virus 
specific antibodies (Abs) can not be detected and when the presence of viral nucleic acid 
may be the only evidence of infection. This particularly true for latent virus infections, 
non cultivable virus, or difficult to cultivate and for virus that grow without a visible 
cytopathic effect and for zoonotic virus PCR is preferred to minimize the risk of exposure 
for laboratory personnel (Bell et al, 1997). The presence of HBV DNA in peripheral 
blood (serum or plasma) is a reliable marker of active HBV replication (Chu and Hussain, 
2002) 
         HBV levels are detectable by 30 days after infection, generally reach a peak at the 
time of clinical acute hepatitis, gradually decrease, and disappear when the infection 
resolves spontaneously. Patients with chronic HBV fail to clear the virus and remain 
HBsAg positive. Such cases may be classified as replicative chronic HBV (high 
HBVDNA levels, hepatitis Be antigen, [HBeAg] positive) or non replicative chronic 
HBV (low or un-detectable HBV DNA levels, hepatitis Be antigen negative) 
(Pawlotskey, 2003; Servoss, 2004). 
         Patients with replicative chronic HBV have more serious liver disease and are more 
infectious than patients with non replicative disease (Chu and Hussain, 2002) In cases of 
acute viral hepatitis with equivocal HBsAg test results, testing for HBV DNA in serum 
may be a useful adjunct in the diagnosis of acute HBV infection, since HBV DNA can be 
detected approximately 21 days before HBsAg appears in the serum (Pawlotskey, 2003; 
Servoss, 2004). 
Testing for HBV DNA levels in serum are used to determine the status of chronic 
HBV infection, by differentiating between replicative (high HBV DNA levels) and non 
replicative (low HBV levels) states. Reactivation of inactive chronic HBV infection 
(HBeAg-negative state) may occur with or without reappearance of HBeAg in serum. In 
patients with HBV infection, detection of HBV DNA is the only reliable confirmation of 
active HBV replication (Chu and Hussain, 2002) 
2.27 Other laboratory and clinical tests:  
 The diagnosis of liver disease depends up on a combination of history, physical 
examination, laboratory testing and sometime radiological studies and biopsy.  
2.27.1 Ultra sound scan of liver: 
 It is a routine test that does not show how much damage there is to the liver but it 
gives an indication of the shape and size of the liver (Mowat       et al, 2001). 
2.27.2 Liver function tests: 
 These are routine tests performed in the investigation of a liver disease, these tests 
are non-specific and in most cases are not true indications of liver dysfunction. They are 
only suggestive liver disease (Mowat et al, 2001). 
 
 
2.27.3 Aspartate aminotransferase (AST): 
 The enzymes AST previously known as glutamate oxaloacetate transaminase GOT, 
is concerned with amino acid metabolism. Large amounts of AST are present in the liver, 
kidneys, cardiac muscle. Small amount of the enzyme are present in the brain, pancreas, 
and lungs. In district laboratories the measurement of AST activity is mainly performed 
to investigate liver disease and myocardial infraction (Cheesbrough, 1998). 
2.27.4 Alanine aminotransferase (ALT): 
 The enzyme ALT formerly known as glutamate pyruvate transaminase (GPT), is 
concerned with amino acid metabolism. ALT is found principally in the liver with only 
small amounts being present in other organs When there is liver cell damage the serum or 
plasma levels of enzymes are raised (Cheesbrough, 1998). 
2.27.5 Albumin: 
 Albumin is produced entirely in the liver and constitutes about 60% of total serum 
protein. It is important in regulating the flow of water between the plasma and tissue 
fluid. When the concentration of albumin is significantly reduced, the plasma osmotic 
pressure is insufficient to draw water from the ties spaces back into the plasma. This leads 
to a build-up of fluid in the tissues, culminating in oedema.  
 Albumin also has important binding and transport function. It binds and inactivates 
substances including calcium, fatty acid, hormones and magnesium. When albumin levels 
are reduced, toxic effects can develop from an increase in unbound substances. Low 
serum albumin concentration indicates poor liver function (Cheesbrough, 1998). 
2.27.6 Bilirubin: 
 Bilirubin is formed from the breakdown of erythrocytes and other haem-containing 
proteins such as myoglobin and cytochrmes. It is two types, un-conjugated (indirect) 
bilirubin, it is not soluble in water and can not be excreted in the urine. It is bound to 
albumin transported in the blood to the liver. This bilirubin is referred to as conjugated 
(direct) bilirubin and is water-soluble (Cheesbrough, 1998). If the liver is not functioning 
well there is a decreased removal of the bilirubin from the blood stream (Mowat et al, 
2001). 
2.27.7 Prothrombin time (PT): 
 Many factors necessary for blood clotting are made in liver. When liver function is 
severely abnormal, their synthesis and secretion into the blood is decreased. The (PT) is a 
type of blood clotting test performed in the laboratory and it is prolonged when the blood 
concentration of some of the clotting factors made by the liver are low. The (PT) can also 
be prolonged in case of vitamin K deficiency and by drugs (Mowat et al, 2001). 
2.27.8 Alkaline phosphatase (AP): 
 Alkaline phosphatase is an enzyme, or more precisely a family of related enzymes, 
produced in bile ducts, intestine, kidney, placenta and bone. An elevation in level of 
serum AP suggests disease of the bile duct (Cheesbrough, 1998).   
2.27.9 Gamma-glutamy transpeptidase (GGT): 
 GGT an enzyme produced in bile ducts that like (AP), may be elevated in the 
serum of patient with bile ducts disease. Measurement of GGT is an extremely sensitive 
test, however, and it may be elevated in virtually any liver disease (Mowat et al, 2001). 
2.28 Treatment: 
 Currently, there is no treatment available for acute hepatitis B. Symptomatic 
treatment of nausea, anorexia, vomiting, and other symptoms may be indicated. 
Treatment of chronic hepatitis B is aimed at eliminating infectivity to prevent 
transmission and spread of HBV, at halting the progression of liver disease and 
improving the clinical and histologic picture, and at preventing HCC from developing, by 
losing markers of HBV replication in serum and liver like HBV DNA, HBeAg, and 
HBcAg. Normalization of ALT activity, resolution of hepatic inflammation and the 
improvement of a patients' symptoms usually accompany these virological changes 
(Hollinger and Liang, 2001; Mahoney and Kane, 1999). 
 There are two main classes of treatment. Antiviral aimed at suppressing or 
destroying HBV by interfering with viral replication (Mahoney and Kane, 1999). Immune 
modulaters aimed at helping the human immune system to mount a defense against the 
virus. 
Currently, chronic hepatitis B is treated with interferon (Gitlin, 1997; Hollinger and 
Liang, 2001; Mahoney and Kane, 1999; Robinson, 1995). The only approved ones are 
interferon-α-2a and interferon- α-2b. Interferons display a variety of properties that 
include antiviral, immunomodulatory, and anti-proloferative effects. They enhance T-cell 
helper activity, cause maturation of B lymphocytes, inhibit T-cell suppressors, and 
enhance HLA type I expression. Patients with acute infection, end stage cirrhosis or other 
major medical problems should not be treated. Interferon- α-2b produces a long-term, 
sustained remission of the disease in 35% of those with chronic hepatitis B, with 
normalization of liver enzymes and loss of the three markers for an active infection 
(HBeAg, HBV DNA, and HBsAg), Complete elimination of the virus is achieved in some 
carefully selected patients (Hollinger and Liang, 2001; Mahoney and Kane, 1999; 
Robinson, 1995; Tassopoulos et al, 1997). 
Interferon therapy for patients with HBV-related cirrhosis decreases significantly 
the HCC rate, particularly inpatients with a larger amount of serum HBV DNA. In 
patients with HBeAg-positive compensated cirrhosis, virological and biochemical 
remission in following interferon therapy is associated with improved survival. In patients 
with chronic HBV infection, the clearance of HBeAg after treatment with interferon- α is 
associated with improved clinical outcomes (Fattovich, 1999; Hollinger and Liang, 2001; 
Ikeda, 1998; Mahoney and Kane, 1999; Niederau, 1996). 
2.29 Prevention and control:  
 
 The prevention of chronic HBV infection has become a high priority in the global 
community (Mahoney and Kane, 1999). 
 Immunization with hepatitis B vaccine is the most effective means of preventing 
HBV infection and its consequences (Center for Disease Control and Prevention, 1991; 
Gitlin, 1997; Hollinger and Liang, 2001; Robinson, 1994; VanDamme and Kane, 1997). 
          HBIG protects by passive immunization if given shortly before or soon after 
exposure to HBV. It is also administered in combination with HBV vaccines to newborns 
of HBsAg positive mothers. The protection is immediate, but of short duration, HBIG is 
not recommended as a pre-exposure prophylaxis because of high cost, limited 
availability, and short-term effectiveness (Gitlin, 1997; Hollinger and Liang, 2001). 
 Preventing HBV transmission during early childhood is important because of the 
substantial likelihood of chronic HBV infection and chronic liver disease that occurs 
when children less than 5 years of age become infected. Integrating HB vaccine into 
childhood vaccination schedules has been shown to interrupt HBV transmission (Center 
for Disease Control and Prevention, 1991). 
          In order to avoid unnecessary risks of HBV infection, patients who depend on 
recurrent transfusion should be vaccinated (World Health Organization, 2002).  
 Universal precautions should be used when handling human blood and body fluids. 
Specific precautions include the use of gloves, protective garments, and masks, when 
handling potentially infectious or contaminated materials. There is no substitute for good 
personal hygiene, strict surveillance, and appropriate environmental control measures to 
limit transmission. Autoclaving and the use of ethylene oxide gas are accepted methods 
for disinfecting metal objects, instruments, or heat-sensitive equipment (Hollinger and 
Liang, 2001).The expense and difficulty of treating hepatitis B medically and by hepatic 
transplantation is in contrast with the fact that the infection can be prevented by 
vaccination. Vaccination campaigns have shown that control of the disease is feasible, 
even in endemic areas. Some countries incorporate hepatitis B immunoglobulin (HIG) in 
their vaccination strategies. In endemic areas, procurement of low cost vaccine, education 
and acceptance, vaccine integration in the expanded program of immunization (EPI), 
prevention of vertical transmission, antibody escape mutations, protective efficacy, long 
term immunity and natural boosting are important questions and issues. Since most HBV 
carriers are unaware of their condition, but pose a significant risk to health care workers 
and other people exposed to their blood, workers are advised to assume that all patients 
are potentially infectious, and should practice "universal precautions" (World Health 
Organization, 2002) 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
MATERIALS AND METHODS 
 
3.1 Collection of samples: 
 A total of 480 blood samples were collected from different group in Khartoum 
State between January and July 2006. Data on respondent background, ideas, attitudes, 
and behavior on various issues in form of a questionnaire were collected, these groups 
include: 
1. Blood donors groups: 280 blood samples were collected from blood donors in 
Khartoum Teaching Hospital. 
2. Haemodialysis patient groups: 100 blood samples were collected from 
haemodialysis patients at Khartoum Center for Kidney Diseases and Bahri Renal 
Centre (National Centre of Kidney Diseases). 
3. Multiple transfused individuals: 20 blood samples were collected from multiple 
transfused individuals at Ahmed Gasim Hospital & Khartoum Teaching Hospital. 
4. Jaundice patients groups: 80 blood samples were collected from jaundice patients 
visiting the Central National Health Laboratory. 
           Venous blood samples were collected using vacutainer containers and needles 
(syringe 5ml). The blood was drawn into the tube without any anticoagulant and the 
blood was allowed to clot at room temperature for no more than 1 hour. The serum was 
removed and placed in a sterile capped microfuge tube and the tube was centrifuged at 
1000 rpm for 5 min at 4oC. The serum was then removed without disturbing the pellet and 
the tubes were stored at -20oC till used.  
3.2 Immuno chromatography technique (ICT) for detection of hepatitis B surface 
antigen (HBsAg) in 480 serum samples: 
The ICT tests were produced from ACON laboratories. San Diego, USA and 
supplied as follows: 
3.2.1 Materials provided: 
a) Test devices contain anti-HBsAg particles coated on the membrane. 
b) Disposable specimen dropper. 
3.2.2 Materials required but not provided: 
a) Specimen collection containers. 
b) Pipette and disposable tips. 
c) Centrifuge 
d) Timer 
3.2.3 Storage and stability: 
          The kits were stored at room temperature or refrigerated (2–30oC). The test devices 
were kept in the sealed pouch until used. The expiry date was observed. 
3.2.4 Test procedure: 
 Specimens (serum) were allowed to reach room temperature          (20–25oC) 
before running the test. Frozen specimens were completely thawed and mixed well prior 
to testing. The test devices were removed from the sealed pouch and placed on clean and 
level surface and used immediately and the test is performed within one hour. Then 3 full 
drops of serum (approx. 100 µl) were transferred into specimen well (S) of the test 
device. Results were read after 10 minutes as indicated by the appearance of the red lines. 
(Fig. 4). 
3.2.5 Interpretation of results: 
a) Positive test: Two distinct redlines appear, one line should be in the control region 
© and another line should be in the test region (T). 
b) Negative test: When one redline appears in the control test region (T). 
c) Invalid test: If no line appeared on the positive control region (C). 
3.3 Direct (sandwich) ELISA for detection of HBsAg in 480 serum samples: 
The ELISA kits were purchased from Shanghai SHC Kehua biotech Co. LTD, 
Shanghai, China and supplied as follows: 
1. 5 micro titer plate 12 x 8 wells (96 tests) strips per plate coated with monoclonal 
anti-HBs (mouse) and sealed in an aluminum bag containing a silica gel bag as 
desiccant. 
2. Conjugate: 1 vial of 6-2 ml/horseradish HRP-labeled guinea-pig anti-HBs. 
3. Positive control: 1 vial of 1.0 ml contain HBsAg but non-reactive for anti-body to 
HIV-1 and HIV-2. 
4. Negative control: 1 vial of 1.0 ml derived from human blood prepared only from 
donations which have been tested for HBsAg as well as for anti-body to HIV by 
reliable method and found to be negative.  
5. Washing solution: 1 bottle of 40 ml concentrated, which must be diluted 1:25 
before use. 
6. Chromogen A: 1 vial of 8.0 ml (contains hydrogen peroxide). 
7. Chromogen B: 1 vial of 8.0 ml contains Teteramethyle benzedine (TMB) and 
Dimethyl sulphoxide. 
8. Stopping solution: 1 vial of 7.0 ml contains (2M H2SO4). 
9. Plate covers: 2 pieces. 
10. Instruction manual: 1 copy. 
3.3.1 Other materials not included in kit: 
1. Distilled or deionized water. 
2. Multichannel pipette and micropipettes capable of delivering 20 – 100 and 1000 µl. 
3. Disposable pipette tips. 
4. An automatic microplate washer. 
5. Microplate mixer 
6. Incubator with high relative humidity, at 37oC. 
7. Timer 
8. Microplate reader equipped with a 450 nm and 630 nm filter. 
9. Absorbent tissue. 
3.3.2 Storage and stability of ELISA kits: 
All kits components were stored at 2–8oC. The bag containing the microtiter plate 
should be brought to room temperature before opening to avoid condensation in wells. 
Unused strips should be stored between 2–8oC tightly sealed in the plastic bag provided 
with the silica gel bag inside. The washing solution once diluted is stored between 2–8oC. 
The chromogen was stored protected from light. 
3.3.3 Test procedure: 
3.3.4 Preparation of reagents: 
 Reagents, test samples, controls, conjugate, diluted wash solution, substrate, 
aluminum bag containing the microplate and the vial containing TMB were allowed to 
come to reach room temperature (20–25oC) before running the assay. All liquid reagents 
were mixed before use. The concentrated washing solution is diluted 1:25 with distilled 
water. All dilutions were made according to the manufacture instructions. 
3.3.5 Assay procedure: 
 Five wells were reserved for one blank, two negative controls and two positive 
controls. Fifty µl of positive control was transferred into each of the two wells, 50 µl of 
negative control was transferred into each of the two wells and remained one blank. 
 Fifty µl of each sample (serum) was distributed to the designated well. Five µl of 
conjugate transferred into each wells (excluding the blank well). The plates were covered 
with a plate sealer, mixed gently and incubated for 1 hour at 37oC. Thereafter, the 
adhesive plate covers were removed and each well was filled with a proximately 300 µl 
diluted washing solution. This process was repeated five times. After the last washing the 
microplates were blotted on absorbent tissue to remove any excess liquid from the wells 
then 50 µl of chromogen A and 50 µl of chromogen B were transferred into each wells of 
the microplate (including the blank well). The plates were covered again with a fresh 
plate sealer and incubated at 37oC for 30 minutes in an incubator. The adhesive plate 
covers were removed and discarded. Then the reaction was stopped by adding 50 µl of 
stopping solution to each well (including the blank well) and mixing completely. The 
spectrophotometer was blanked at 450 nm with blank well and absorbances of each well 
were read within 10 minutes. 
3.3.6 Calculation of the results: 
 The judgment of results is based on the photometric reading data. 
 N = The mean absorbance of the negative control 
 P = The mean absorbance of positive control 
 S = The absorbance of the test sample. 
 
3.3.7 Calculation of cut-off value: 
 The cut-off value is 2.1 x N 
1F N is less than 0.05 then N= 0.05 
1F N is greater than or equal, let N equal its actual value. 
3.3.8 Reading of test result: 
The presence or absence of HBsAg in samples analyzed was determined by 
relating the absorbance value of each sample to the cut-off value of the technique. 
A test is positive if S > cut-off value 
A test is negative if S < cut-off value 
A test-run is only valid if N < 0.1 and P > 1.0. 
3.3.9 Interpretation of the test: 
 If the test value of a serum was above the calculated cut-off value the test serum 
was considered positive and if the test value was lower than the cut-off value, the sample 
was considered negative for the presence of HBsAg. However, sera having test value 
equal to the cut-off value, should be retested in duplicates and if one duplicate has a value 
above the cut-off value the test was considered positive even if the other duplicate value 
was below the cut-off value.  
 
 
 
3.4 Polymerase chain reaction (PCR): 
3.4.1 DNA extraction: 
 Extraction of viral DNA from serum was made according to Tripathy (2003) using 
the phenol-chloroform extraction method with some modification. o.5 ml of cell lysis 
solution (10 mm Tris-HCl, pH 7.4, 100 mm NaCl, 10 mm EDTA, 0.5% SDS) and 2% B 
mercaptoethanol) (Appendix 1) were added to 2 ml eppendorf tube containing 500 µl of 
serum, then 15 µl of protinase K solution (10 mg/ml) (Appendix 2) were added and the 
mixture was vortixed for few seconds, incubated at 55oC for 4 hours or at 37oC for 
overnight. The sample was vortixed after every 15 minutes during incubation. 10 ul of 
RNase were added and the tube was inverted 25 times, and then incubated at 37oC for 15 
minutes. DNA was extracted from the digest in the presence of equal volume of phenol-
chloroform-isoamy-alchohol (50:2:48). The extraction last for 30 second with mixing by 
inverting eppendorf tube followed by centrifugation at 10.000 rpm for 1 min. The tube 
content will divided into three layers, phenolic phase, interphase (protein) and an aqueous 
phase. The aqueous phase (which contains the nucleic acids) was removed to another 
eppendorf tube for further extracted with phenol-chloroform and this step was repeated 
for three times. The last aqueous phase was replaced to another 1.5 ml eppendorf tube and 
3 M Na acetate was added in a volume equivalent to 1:10 of the aqueous phase and equal 
volume of isopropanol alcohol was added, mixed and stored at -20o overnight. The DNA 
was pelleted by centrifugation at 13000 rpm for 45 minutes at +4oC. Then the DNA pellet 
was washed with 300 µl 70% alcohol and centrifuged at 13000 rpm for 15 min at +4oC, 
and the ethanol was poured off. The tube was then allowed to dry for 10 - 15 minutes. 50 
µl of DNA hydration solution was added and the DNA was dissolved by incubating at 
65oC for 1 hour and then the DNA was stored at +4oC until used. 
3.5 Primer selection and PCR condition: 
3.5.1 Reconstitution of primers: 
 Primers were purchased as freeze dried oligonucleotides (MWG, German) 
reconstituted with 473 DDW to get a final concentration of 100 pmol/µl and left 
overnight at +4oC. Working solutions for each primers were prepared so as to contain 10 
pmol/µl of oligonucleotides. 
 The sequences of the oigonucleotide primers used in this study are specific primers 
for surface antigen genome region specific or ss genome region specific. These primers 
are expected to give PCR product size of 477 bp (Table 3) (Crirish and Kotwal., 1998). 
3.5.2 PCR for hepatitis B virus: 
 PCR was performed in a final volume of 50 µl including 5 µl of template DNA, 0.5 
µl of DNA polymerase, 2 µl HBV2R and HBVS primers, 3 µl of Mgcl2, 5 µl PCR buffer, 2 
µl of dNTP and then 30.5 µl of distilled water, were added to complete the volume to 50 
µl. After the initial denaturation for 30s at 94oC, the DNA was amplified for 35 cycles of 
30s of denaturation at 94oC, 30s of annealing at 56oC and 9 min of extension at 68oC, 
with a final extension step of 10 min at 68oC. The amplification was performed in a T 
personal thermocycler (Biometra, German). 
 
 
 
 
 
 
Table (3): Sequence of the oligonucleotide primers targets and expected PCR product size 
(Girish and Kotwal., 1998).  
 
Primer and 
Direction Sequence 
Product 
size 
Amplification 
target 
HBV 2R  5. AAG CCC CTA CGR ACC ACT GAA CAA ATG GCA C-3 477bp 
HBS Ag 
(surface antigen) 
or ss genome region 
HBVS 
 
5- ATA CCA CAG AGT CTA GAC 
TCG TGG TGG ACT-3 
- - 
 
3.5.3 Analysis of PCR products: 
3.5.3.1 Gel electrophoresis: 
The PCR products (amplicons) were separated electro-phoritically in 1.5% agarose 
gels (Appendix 3.1) (SIGMA) 10 µl of 100 bp DNA ladder (INVTROGEN) (Appendix 
3.4) was loaded in the first slot of the gel. Then 16 µl of the PCR product was mixed with 
4 µl of loading Dye (Appendix 3.3) and loaded on the rest wells.  
Electrophoresis was performed in a Mini gel electrophoresis (Biometra) using 75 
volt for 45 min after the gel was covered with TAE buffer (Appendix 3.2) using standard 
power Pack P25 (Biometra). DNA bands were visualized using the Bio Doc analyze gel 
documentation system (Biometra). 
3.5.3.2 Interpretation: 
Negative results indicated that HBV DNA is not detected in the specimen. Positive 
results indicated that HBV DNA is detected in the specimen. 
 
3.6 Indirect ELISA for the detection of HCV-antibodies in serum samples positive 
for HBsAg : 
3.6.1 ELISA kits: 
 The ELISA kits were purchased from Biokit, A.S. Spain and supplied as follows: 
1. 5 microtiter plate 12 x 8 wells coated with HCV recombinant antigens. 
2. Concentrated conjugate (1-5 ml). Rabbit anti-human IgG antibodies conjugated 
with peroxidase, contains red dye, preservatives and protein stabilizers. To be 
diluted 1/51 with the conjugate diluents just before use.  
3. Conjugate diluents. Tris buffer containing yellow dye, additives and preservative. 
4. Sample diluents. Tris buffer with protein stabilizers and sodium acids as 
preservative.  
5. Concentrated washing solution is phosphate buffer containing 1% tween 20 and 
0.01% thimerosal. 
6. Substrate solution which is citrate-acetate buffer containing hydrogen peroxide. 
7. Chromogen which is 3, 31, 5, 51-tetramethyl benzidine (TMB) dissolved in 
dimethyl sulphoxide (DMSO). 
8. Positive control which is diluted heat inactivated human serum containing 
antibodies to HCV. Contains sodium acids as preservative and green dye.  
9. Negative control which is dilute human serum negative for anti-HCV. Contains 
sodium azide as preservative and yellow dye. 
10. Stopping solution which is 1 N sulphuric acid. 
11. Adhesive seals to cover plate during incubation. 
12. Resealable bag for storage of unused wells.  
3.6.2 Other materials not included in the kit 
1. Distilled or deionized water. 
2. Multichannel pipette and micropipettes. 
3. Automated wash system. 
4. Microplate reader with 450 nm filter 
5. Incubator with high relative humidity, at 37oC. 
3.7 Storage of ELISA kits: 
 All kits components were stored at 2–8oC. The bag containing the microtiter plate 
was brought to room temperature before opening to avoid condensation in the wells. 
Unused strips were stored between 2–8oC tightly sealed in the plastic bag provided with 
the silica gel bag inside. The washing solution when diluted was stored between 2–8oC. 
The diluted conjugate is stable for 15 days at 2–8oC. The chromogen was stored protected 
from light whereas substrate –TMB solution was prepared according to the manufacture 
instructions. 
3.8 Test procedure: 
3.8.1 Preparation of reagents: 
 Reagents were allowed to reach room temperature (20–25oC) before running the 
assay. All liquid reagents were mixed before use. The concentrated washing solution was 
diluted (1/10) with distilled water. The concentrated conjugate was diluted (1/51) with the 
conjugate diluent. All dilutions were made according to the manufacture instructions. 
3.8.2 Assay procedure: 
 Six wells were reserved for one blank, three negative controls and two positive 
controls, each filled with 200 µl of the appropriate serum control. Two hundred µl of 
sample diluents and 10 µl of each sample were distributed to the designated wells. The 
plates were covered with adhesive seals, mixed gently and incubated for 1 hour at 37oC. 
Thereafter the adhesive plate covers were removed and the content was discarded by 
aspiration and each well was filled approximately with 300 µl diluted washing solution. 
The process was repeated five times. After the last washing the microplates were blotted 
on absorbent tissue to remove any excess liquid from the wells. Then 100 µl of diluted 
conjugate were transferred into each well of the microplates, except the blank. The plates 
were covered again with the adhesive seals and incubated for 30 minutes at 37oC. 
 The adhesive plate covers were removed and discarded. The plate's contents were 
aspirated and washed six times with washing buffer. Then 100 µl of substrate- TMB 
solution were added to each well. All plates were incubated uncovered for 30 minutes at 
room temperature. The reaction was stopped by adding 100 µl of stopping solution in the 
same sequence and time intervals as for the substrate-TMB addition. The 
spectrophotometer was blanked at 450 nm with the blank well and the absorbencies of 
each well were read within 30 minutes. 
 
3.8.3 Reading of the result: 
 For the validity of the assay the accomplishment of the following points were 
observed. 
a) Negative control means (NC): Absorbance of individual negative control values 
were less than or equal to0.200 OD. 
b) Positive control means (PC): It was equal or greater than 0.800 OD. 
c) The presence or absence of anti-HCV antibodies in the samples analyzed was 
determined by relating the absorbance value of each sample to the cut-off value of 
the technique. This value was the mean value obtained from the negative control 
plus 0.300 OD. 
 Cut-off = NC + 0.300 OD 
3.9 Interpretation of the test: 
 If the test value of a serum was above the calculated cut-off value, the test serum 
was considered positive and if the test value was lower than the cut-off value, the sample 
was considered negative for the presence of HCV-antibodies. However, sera had test 
values equal to the cut-off value, these sera were retested in duplicates and if one 
duplicate had a value above the cut-off value the test was considered positive even if the 
other duplicate value was below the cut-off value.  
3.10 Immuno chromatography technique (ICT)  for detection of HCV-antibodies in  
serum  samples positive for HBsAg : 
The ICT test  kits purchased from ACON laboratories, San Diego, USA and  supplied as 
follows 
3.10.1 Materials provided:  
a) Test devices  
b) Disposable specimen dropper. 
C) Buffer    
3.10.2 Materials required but not provided: 
a) Specimen collection containers. 
b) Pipette and disposable tips. 
c) Centrifuge 
d) Timer 
3.10.3 Storage and stability: 
          The kits were stored at room temperature or refrigerated (2–30oC). The test devices 
were kept in the sealed pouch until use. The expiry date was observed. 
3.10.4 Test procedure: 
 Specimens (serum) were allowed to reach room temperature (20–25oC) before 
running the test. Frozen specimens were completely thawed and mixed well prior to 
testing. Then the test device was allowed to equilibrate at the room temperature. The test 
devices and buffer were removed from the sealed pouch and placed on clean and level 
surface and used immediately and the test was performed within one hour. Then 5 µl full 
of serum were transferred into specimen well (S) of the test device and then two drops of 
buffer (approximately 80µl) were added carefully to avoid trapping air bubbles in the 
specimen well. Results were read after 10 minutes as indicated by the appearance of the 
red lines. 
3.10.5 Interpretation of results: 
a) Positive test: Two distinct redlines appear, one line was in the control region © and 
other line was in the test region (T). 
b) Negative test: When one redline appeared in the control test region (T). 
c) Invalid test: when no line appeared on the positive control region (C). 
3.11 Statistical Analysis : 
            Stata NT/ 98 Germany was used for analysis of the data collected.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
RESULTS 
 
    The presence of HBsAg, HBV-DNA in sera of different groups and anti-HCV 
antibodies detected in HBsAg-positive patients as marker of co-infection in sera of 
different groups of patients were as follows: 
4.1 ICT results: 
  280, 20, 100 and 80 blood samples were collected from blood donors, multi-
transfused, haemodialysis and jaundiced patients and 15 (5.3%), 2 (10%), 23 (23%) and 9 
(11.5%) samples were found positive for HBsAg respectively when screened by ICT 
(Table 4 and Fig. 2,7). 
4.2 ELISA results: 
  In contrast to the previous test samples when tested by ELISA using HBsAg 
sandwich ELISA we found 16 (5.7%), 2 (10%), 23 (23%) and 9  (11.2%) samples 
positive for HBsAg when blood donors, multi-transfused, haemodialysis and jaundiced 
patients were tested respectively (Table 5 and  Fig. 3,8,9). 
4.3 Comparison between ICT and ELISA tests of HBsAg: 
   In comparison between ICT and ELISA detected one positive samples that were 
found negative by ICT test. However, there was a very high agreement between ICT and 
ELISA and no statistical significant difference was obtained by the application of Stata 
NT/98 and both assays were sensitive, specific and reliable (Tables 10, 11, and 15).  
4.4 PCR Results: (Detection of HBV-DNA): 
 Fifteen serum samples with HBsAg positive and 10 samples with HBsAg negative 
screened by ICT and ELISA were investigated to detect HBV-DNA using the PCR. We 
detect HBV-DNA in 45 (90%) samples of HBsAg positive. HBV-DNA detected in eleven 
(68.7%), two (100%), 23 (100%) and nine (100%) samples collected from blood donors, 
multi-transfused, haemodialysis and jaundiced patients, and in two (20%) samples 
negative for HBsAg collected from blood doors (Tables 8,9,14 and  Fig.6,12,13,14,15). 
4.5 ELISA results for HCV-antibodies in HBsAg positive samples: 
    In contrast to the previous test samples when tested by ELISA using recombinant 
HCV-antigens we found 2 (12.5%) blood donors and one (4.3%) haemodialysis patients 
were positive for HCV-antibodies when patients were tested respectively (Table 7& Fig. 
5,10). 
4.6 ICT results of HCV-antibodies in HBsAg positive samples: 
.   Sixteen, 2, 23 and 9 HBsAg positive samples from blood donors, multi-
transfused, haemodiaysis and jaundice patients were tested and one (6.2%) blood donors 
one (4.3%) haemodialsis patients samples were positive for HCV-antibodies respectively 
when screened by ICT (Table 6 and Fig. 4,11). 
4.7 Risk factors associated with HBsAg positive samples: 
 Tables 12 and 13 summarized data obtained from the questionnaire and all risk 
factors that might contribute to HBV infection. All patients who were positive for HBsAg 
had an age ranging between 17 – 63 years. We found all haemodialysis patients had 
received blood transfusion and HBV infection in this group was probably blood 
transfusion mediated disease. Sexual practice (12%) sharing needles (14%) and surgical 
instruments (30%) represented a risk factor. Intravenous drug users and tattooing had no 
role in predisposition to the disease. In the groups studied high incidence of HBsAg 
(23%) was found in haemodialysis group and probably haemodialysis machine had a role 
in transmission of the disease.  
 
 
 
 
Table 4:   HBsAg positive individuals in various groups screened by ICT test. 
   
Group tested Number screened 
Number of 
HBsAg positive 
Number of 
HBsAg% 
positive 
Blood donors 280 15 5.35% 
Multi-transfused 20 2 10% 
Haemodialysis patients 100 23 23% 
Jaundice patients 80 9 11.5% 
Total 480 49 10.2% 
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      Fig. 2: HBsAg positive individuals in various groups screened by ICT test. 
 
            * Pts = Patient. 
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  Table 5:  HBsAg positive individuals in various groups screened by ELISA test. 
 
 
 
 
 
 
 
 
 
 
 
 
          Group tested Number screened 
Number of 
HBsAg positive  
Number of 
HBsAg% 
positive 
Blood donors 280 16 5.7% 
Multi-transfused 20 2 10% 
Haemodialysis patients 100 23 23% 
Jaundice patients 80 9 11.2% 
               Total 480 50 10.4% 
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Fig. 3: HBsAg positive individuals in various groups screened by (ELISA) test. 
  
       * Pts = Patient. 
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Table 6: HCV-antibody positive individuals in groups of HBsAg positive screened by 
ICT test  
 
 
Group tested Number screened 
Number of HCV-
antibodies positive  
Number of 
HCV-
antibodies%
positive 
Blood donors 16 1 6.2% 
Multi-transfused 2 - - 
Haemodialysis patients 23 1 4.3% 
Jaundice patients 9 - - 
Total 50 2 4% 
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Fig. 4: HCV-antibody positive individuals in groups of HBsAg positive  screened by ICT 
test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7: HCV-antibody positive individuals in groups of HBsAg positive  screened by 
ELISA test  
 
 
Group tested Number screened 
Number of HCV-
antibodies positive 
Number of 
HCV-
antibodies% 
positive 
Blood donors 16 2 12.5% 
Multi-transfused 2 - - 
Haemodialysis 23 1         4.3% 
Jaundice patients 9 - - 
            Total 50 3 6% 
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Fig. 5: HCV-antibody positive individuals in groups of HBsAg positive screened by 
ELISA test  
 
 
* Pts = Patient. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8:  HBV DNA detection in HBsAg positive patients in various group screened by 
PCR. 
 
Group tested 
Number of 
HBsAg 
positive  
Number of HBV-
DNA positive   
Number of 
HBV-DNA% 
positive   
Blood donors 16 11 68.7% 
Multi-transfused 2 2 100% 
Haemodialysis 23 23 100% 
Jaundice patients 9 9 100% 
Total 50 45 90% 
 
 
 
 
Table 9:   HBV DNA detection in samples negative for HBsAg screened by ELISA and 
ICT test. 
Group Tested 
Number of  
HBsAg 
Negative 
HBV DNA 
Positive 
Number of  
HBV DNA% 
Total of HBV 
DNA%  
Blood Donors 10 2 20 % 20 % 
 
 
 
 
 
 
 
05
10
15
20
25
30
35
40
45
50
Blood Donors Multiple transfusion Hemodialysis pts Jaundice pts Total
Screened
Positive
 
    Fig. 6:  HBV DNA detection in HBsAg positive patients in various groups. 
 
  * Pts = Patient. 
     
 
           
 
 
  
 
 
Table 10:   Sensitivity and Specificity of ELISA and ICT Test. 
     Test          Sensitivity %      Specificity % 
ELISA 100 % 99.07 % 
           ICT 100 % 99.07 % 
dividual
                               
 
 
 
 
 
 
 
Table 11:  Agreement between ELISA and ICT Test (Kappa Statistic). 
      Tests    Agreement %       Kappa 
    ELISA & ICT          99.79 %          0.9* 
           
      * Very Good Agreement  
 
 
 
 
 
 
 
 
 
 
 
Fig. 7:  Detection of HBsAg by Immune-chromatography Test (ICT). 
  
 
 
 
 
  
 
  
 
Fig. 8:  Detection of HBsAg by ELISA test       
  
 
  
 
 
Fig. 9: Detection of HBsAg by ELISA test       
Fig. 10 :  Detection of HCV-anti-bodies by ELISA  test 
 
Fig. 11: Detection of HCV–antibodies by Immune-chromatography Test (ICT). 
 
 
 
 
 
           Fig. 12: Ethidium bromide stained agarose gel (1.5%) electrophoresis of HBV 
PCR products with a band of expected size 477 bp, carried out on DNA samples 
extracted from serum, Lane M: 100 bp ladder, with fragment size indicated 
along the left edge of the figure, Lane, 1 positive control, Lane, 7 negative 
control, Lane, 2-3-4-5-6 serum samples, sample 4 showed weak Positive.  
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Fig. 13 : Ethidium bromide stained agarose gel (1.5 %) electrophoresis of HBV PCR 
products with a band of expected size 477 bp, carried out on DNA samples 
extracted from serum, Lane M: 100 bp ladder, (Arrow shows 500 and 400 bp 
band), Lane, 7 negative control, Lane, 1- 2-3-4-5-6 serum samples. 
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Fig. 14 : Ethidium bromide stained agarose gel (1.5 %) electrophoresis of HBV PCR 
products with a band of expected size 477 bp, carried out on DNA samples 
extracted from serum, Lane M: 100 bp ladder, (Arrow shows 500 and 400 bp 
band), Lane,7 negative control, Lane, 1- 2-3-4-5-6  serum samples . 
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Fig. 15 : Ethidium bromide stained agarose gel (1.5 %) electrophoresis of HBV PCR 
products with a band of expected size 477 bp, carried out on DNA samples 
extracted from serum, Lane M: 100 bp ladder, (Arrow shows 500 and 400 bp 
band), Lane, 1 negative control, Lane, 2-3-4-5  serum samples. 
 
 
 
CHAPTER FIVE 
DISCUSSION 
 
           Hepatitis B (HB) is a major cause of death worldwide, with more than 2 million 
deaths per year mainly because of the sequelae of chronic liver disease, liver cirrhosis and 
hepatocellular carcinoma (HCC). The disease remains a major problem in developing 
countries. The HB viruses (HBV) express antigens such as HBsAg (surface antigen) on 
its surface, provoking both cell-mediated and humoral responses (Shobokshi, 1990; Gill 
and Beeching, 2004). 
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              Several studies were published on sero-prevalence of HB in the Sudan (Hymas et 
al., 1989; McCarthy et al.,1989; Elshafie.,1992; Khalil et al., 1996; Fahal et al., 1997; 
and Suliaman et al.,1997). )    
           This study is focused on the molecular and serological diagnosis of HBV and 
determination of co-infection with HCV in risk groups in Khartoum state, Sudan. A 
number of 480 serum samples were collected from blood donors, haemodialysis, multi-
transfused and jaundice patients. 
        Out of 480 samples 49 (10.2%) were found positive for  HBsAg, when tested by ICT 
test, while 50 samples (10.4%) were found positive for HBsAg, when tested by ELISA 
test .   
           According to Pawlotskey et al. (1998) HBsAg one step test will only indicate the 
presence of HBsAg in the sample and should not be used as the sole criteria for diagnosis 
of hepatitis B infection. The intensity of the red colour in the test region (T) in ICT may 
vary depending on the concentration of HBsAg present in the sample. Therefore, any 
shade of red color that develops in the test region should be considered positive. 
 When we compared the ELISA and ICT test the ELISA test detected one more 
positive sample that were negative by ICT test. Our study showed a very high agreement 
between ICT assay and ELISA test 99.79 % and no statistical significant difference was 
obtained by the application of Stata NT/98 and both assay were sensitive, specific and 
reliable tests.   
          The ELISA test is very sensitive in detecting HBs antigen, the presence of these 
antigens is considered as marker for HBV infection (Pawlotskey et al, 1998). 
          In this study HBV infection is found high among haemodialysis patients (23%). 
This figure is slightly lower than that obtained by Suliman et al. (1997) who found a 
prevalence of  27.7% of HBV among haemodialysis patients in Khartoum Kidney 
Dialysis Center. However, the dialysis process itself and the level of hygienic standard 
may influence the risk of HBV infection, this may explain differences found between 
dialysis centers in one country. 
 Dialysis patients have an increased risk of exposure to parenterally transmitted 
hepatitis virus and that haemodialysis machine and parenteral medicine may be 
considered risk factors in HBV transmission among HBsAg positive patients (Pereira, 
1992). The present study is in support of this assumption and 46% of the positive HBsAg 
have a history of exposure to haemodialysis machine.  
 Multiple blood transfusions seems to be an important risk factor in the acquisition 
of HB infection. Nonetheless screening of blood donors and blood products for HBsAg 
has been shown to be highly effective in preventing transmission and post-transfusion of 
hepatitis B virus and eliminate the risk of infection (Chopra, 1985). 
          In the present study we detected HBV-DNA by PCR in 45 samples out of 50 
samples (90%) positive for HBsAg by ELISA test. Search of the literature revealed lower 
detection rate. Chen et al. (1995) detected Hepatitis B virus (HBV) DNA in 39 of the 116 
samples with HBsAg positive (34%). Mas et al. (1990) reported that Hepatitis B virus 
DNA was found in only two patients out of 33 patients, one was a chronic HBsAg carrier. 
However high detection rate (98.5%) of HBV DNA during HBsAg and HBeAg 
antigenemia was reported By Quint et al. (1990). 
          In out of 10 samples the PCR detected two (20%) positive HBV DNA samples 
collected from blood donors that were negative for HBsAg by ICT and ELISA tests. This 
result agrees with Rodrigues. (2001) who reported that the presence of HBV DNA in 2/32 
patients with past HBV infection in a group that indicates the low replicative state of 
HBV even after the disappearance of HBsAg. Chen et al. (1995) reported that the HBV 
DNA can be detected in the absence of HBsAg. 
       Similar previous study was done by Brechot et al. (1985) who reported that HBV 
DNA was detected in only 5 of 88 samples, 3 of which were from patients with no 
serologic marker for HBV. 
        In this study we found that there is a good evidence that some individuals with HBV 
infection as detected by PCR do not have detectable HBsAg in their serum. We suggest 
that such cases may be either from patients with recent infection, when the sample was 
obtained during the sero-negative window phase or from patients injected with mutated 
hepatitis BV surface antigen or the concentration of HBsAg in the samples was below the 
detectable level. 
           Our results show a small but significant fraction of blood donors whose sera are 
HBsAg negative by the most sensitive tests (ELISA) are positive by PCR. Accordingly, 
these blood donors are potential  transmitters of HBV infection to recipients of their 
blood. Accordingly, PCR should be introduced to screen blood donors negative by 
ELISA test to be sure that their blood is not infectious. 
            HBV and HCV co-infection, causes frequently chronic active hepatitis. Both types 
of infections may cause fulminant hepatitis (Robinson, 1995). In this study out of 50 
samples positive for HBsAg only two (4%) were found positive for HCV-antibodies 
when tested by ICT. However, these 2 samples in addition to another one (6%) were 
positive by ELISA using recombinant HCV-antigen. Vary. (2006) reported that one 
serum sample was positive to anti-HCV out of 175 HBsAg-positive blood donors.  
            Chiaramonte et al. (1999) reported that HBV and HCV co-infection convey 
increased risk for develop cirrhosis and hepatocellular carcinoma. Accordingly, the 3 
patients with HBV and HCV co-infection detected in the present study are likely to 
develop cirrhosis and hepatocellular carcinoma. 
            The presence of HCV infection in Sudan was previously reported. McCarthy et al. 
(1994) reported that the 3% of studied population were found positive for HCV-
antibodies in Juba, southern Sudan. Mohamed. (2006) reported the prevalence of HCV 
3.4% among blood donors, mluti-transfused and haemodialysis patients and Suliman. 
(1995) reported that the prevalence of HCV infection in Sudanese blood donors, multi-
transfused and dialysis patients is relatively low compared with those shown by data from 
other countries. However, co-infection of HBV and HCV  in the Sudan was reported for 
the first time in the present study. 
 Among the individuals positive for HBsAg by ELISA 30% of them have been 
exposed to different surgical operation. These results showed that surgical instruments 
might be also implicated in transmission of HB infection in Sudan. Tattooing and 
intravenous drug users were not found to be risk factors in this study. Accordingly these 
two risk factors seem not to play any role in transmission of HBV in Sudan. Our results 
disagree with Chopra (1985) who considered tattooing and intravenous drug users as risk 
groups. 
         In this study haemodialysis machine (46%), injury by contaminated needles (14%), 
sexual practice (12%), blood transfused (66%) and surgical instruments (30%) represent 
risk factors for transmission of HBV infection. 
 In this study only 4 patients (8%) have background about how HBV is transmitted 
and how it is prevented. According to the data obtained from the questionnaire this is 
probably due to the lack of professional and public education. In this study it has been 
found that infection with hepatitis viruses may be predisposed by more than one risk 
factors. 
 
 
 
 
 
 
 
 
CHAPTER Six 
CONCLUSION 
 
• There was a very high agreement between ICT and ELISA and no statistical 
significant difference was obtained by the application of Stata NT/98 and both 
assays were sensitive, specific and reliable. 
•   High incidence of HBsAg (23%) was found in haemodialysis patients and 
probably haemodialysis machine have a role in the transmission of the disease. 
•  In this study we detected the HBV DNA in HBsAg-negative samples and suggests 
that multiplication of HBV may occur in the absence of any conventional serologic 
marker for HBV. 
•  In this study only 4 patients (8%) have background about how HBV is transmitted 
and how it is prevented. According to the data obtained from the questionnaire this 
is probably due to the lack of professional and public education. In this study it has 
been found that infection with hepatitis viruses may be predisposed by more than 
one risk factors. 
• ICT is good as ELISA for screening for HBsAg and HCV-anti-bodies. 
• There is a serious lack of information and meaningful data due to stigmatization 
view. 
• Public awareness regarding HBV infection is low. 
 
 
RECOMMENDATIONS 
  *       PCR should be introduced to screen blood donors negative by ELISA 
            test to be sure that their blood is not infectious. 
*      In order to avoid unnecessary risk of HBV infection, patients who depend on 
recurrent transfusion should be vaccinated . 
* Blood donors must be tested for HBsAg before transfusion to recipient.  
* Haemodialysis patients positive to HBsAg, must have separate machine. 
* Surgical and tattooing instruments must be well sterilized before each operation. 
* Isolation of patients with HBV DNA could be beneficial for preventing the 
dissemination of HBV among haemodialysis patients.    
* HBsAg carriers should be prohibited from donating blood for transfused. 
* persons with antigen-positive hepatitis B should be considered infectious and 
control measures by taken with respect to potentially infectious material, such as 
blood and blood-contaminated secretions and body secretions.  
* Persons found to have a positive antigen test in the course of diagnostic studies, 
blood donors testing or testing after know exposure to infection with hepatitis B 
should be informed and the test should be repeated.  
* Persons with confirmed positive test should be evaluated for the presence of liver 
disease and monitored to determine whether the antigen persists. 
* Renal dialysis patients must be tested for hepatitis B antigen and HCV-antibodies 
before each dialysis or at least monthly. 
*        Education programmes : a comprehensive information, education and 
communication approach is needed to raise awareness levels in the general 
population and in high risk groups using all communication channels to provide 
appropriate messages on HBV and HCV transmission, prevention and control. 
*       For person whose sexual behaviors place them at risk for HBV and HCV infection, 
correct and consistent use of the male latex condom can reduce the risk of HBV 
and HCV transmission. However, no protective method is 100 percent effective, 
and condom use cannot guarantee absolute protection against any sexually 
transmitted disease (STDs) 
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Appendix (1) 
 
1. Preparation of cell lysis buffer (ph.7.4):                                                  
     1. 10 mM Tris Hcl.         0.121 gm                                                    
2. 10 mM EDTA.             0.29gm                                                     
3. SDS. (0.5%)                 0.5 gm                                                      
4. Mercaptoethanol 2%     2ml                                                          
5. 100mM NaCl.              0.58gm                                                     
Complete to 100ml of distil water.                                                         
 
2. Preparation of protinase K (10mg/ml):                                                    
0.01gm of protinase K was added to 1 ml of distill water.                           
 
3. Preparation of materials for gel electrophoresis:                                   
3.1 Agarose 1.5%:                                                                                         
1.5 gm of agarose (SIGMA) was dissolved in 100 ml TAE buffer                             
heated in a microwave for 45seconds, left to cool and poured onto electrophoresis.                                      
 
3.2 TAE Buffer:                                                                                            
                            40mM Tris-Hcl (ph 8.0)           40ml                               
                            20mM Na-acetate                       20ml                              
                           EDTA Powder (292.25MW)   5843gm                            
                           Complete to one liter.                                                   
 
3.3 Loading dye:                                                                                          
                           Bromophenol Blue                  11%                                    
                           Glycerol                                   40µl                                    
                           DDW                                      50µl                                     
 
3.4  100 bp Ladder (INVITROGEN):                                                       
                            Ladder (1.0 ug/ul)                    20ml                                  
                           Blue dye                                   80ml                                  
3.5.Ethidium bromide:                                                                                      
Stock solution (PROMEGA, Madison)       10mg/ml 
And protected from light. 
 
 
 
Table 12:  Data obtained from the questionnaire  
 
PBT = Previous Blood Transfused  __ BD = Blood donate __OP = operations __ ta = tattooing __ ivdu = 
intravenous drug users __ ad = alcoholic drink ___ Rpsc = regular partener sexual contact __ HM = 
heamodialysis Machine ___ HBvac = Hepatitis B vaccine  AHBT = Anti-hepatitis B treatment  __ injcn = 
injured by contaminated needles ___HBTw = Hepatitis B Transmission ways ___ Sc = sexual contact __M = 
Male   ____ F = female 
Table 13: Risk factor associated with HBV positive samples in each group. 
NO 
Of 
Sample
PBT BD OP TA IVDU Ad RPsc HM 
INJ
CN 
 
Sc 
14 + - - - - - + + - - 
NO 
Of 
Sample 
sex age PBT BD op ta Ivdu Ad RPsc HM HBvac 
AH
BT injcn HBTw sc 
14 M 26 Yes No NO NO NO NO Yes Yes NO NO NO NO NO 
30 M 31 yes Yes Yes NO NO NO Yes Yes NO NO NO NO NO 
36 M 17 Yes NO NO NO NO NO NO Yes NO NO NO NO NO 
37 F 25 Yes NO NO NO NO NO NO Yes NO NO NO Yes NO 
40 M 17 Yes NO NO NO NO NO NO Yes NO NO NO NO NO 
41 M 45 Yes NO Yes NO NO NO Yes Yes NO NO NO NO NO 
42 F 27 Yes NO NO NO NO NO Yes Yes NO NO NO NO NO 
43 M 31 Yes NO NO NO NO Yes Yes Yes NO NO NO NO NO 
44 M 22 Yes Yes NO NO NO NO NO Yes NO NO NO NO NO 
50 F 35 Yes NO Yes NO NO NO Yes Yes NO NO NO Yes NO 
57 M 40 Yes NO NO NO NO NO Yes Yes NO NO NO NO NO 
58 M 35 Yes Yes NO NO NO NO Yes Yes NO NO NO NO NO 
59 M 41 Yes NO NO NO NO Yes Yes Yes NO NO NO NO NO 
60 M 38 Yes NO NO NO NO NO Yes Yes NO NO NO NO NO 
70 F 52 Yes NO Yes NO NO NO Yes Yes NO NO NO NO NO 
78 M 49 Yes NO NO NO NO Yes Yes Yes NO NO NO NO NO 
83 M 39 Yes NO NO NO NO NO Yes Yes NO NO NO NO NO 
84 M 47 Yes NO NO NO NO NO Yes Yes NO NO NO NO NO 
85 M 20 Yes Yes NO NO NO NO NO Yes NO NO NO NO NO 
89 M 34 Yes NO NO NO NO NO NO Yes NO NO NO NO NO 
92 M 28 Yes Yes NO NO NO NO Yes Yes NO NO NO NO NO 
95 M 37 Yes NO NO NO NO NO Yes Yes NO NO NO NO NO 
98 M 29 Yes NO NO NO NO NO NO Yes NO NO NO NO NO 
109 F 43 Yes NO Yes NO NO NO Yes NO NO NO NO NO NO 
118 M 63 Yes NO NO NO NO NO Yes NO NO NO NO NO NO 
119 F 26 No NO NO NO NO NO NO NO NO NO Yes NO NO 
143 M 50 NO NO Yes NO NO NO Yes NO NO NO NO NO NO 
149 F 27 NO NO NO NO NO NO Yes NO NO NO Yes Yes NO 
159 F 35 Yes NO NO NO NO NO Yes NO NO NO NO NO NO 
167 M 60 Yes NO Yes NO NO NO Yes NO NO NO NO NO Yes 
171 M 31 NO Yes NO NO NO Yes NO NO NO NO Yes NO NO 
174 M 40 Yes NO NO NO NO NO Yes NO NO NO NO NO NO 
181 M 38 NO NO NO NO NO NO Yes NO NO NO Yes NO NO 
190 M 35 Yes NO Yes NO NO NO Yes NO NO NO NO NO Yes 
211     M 30 NO Yes NO NO NO NO NO NO NO NO NO NO NO 
234 M 27 NO NO NO NO NO NO NO NO NO NO Yes NO Yes 
250 M 18 NO NO NO NO NO NO NO NO NO NO NO NO NO 
282 M 25 NO Yes NO NO NO NO NO NO NO NO Yes NO NO 
307 M 36 Yes NO Yes NO NO NO Yes NO NO NO NO Yes NO 
320 M 39 NO Yes Yes NO NO NO Yes NO NO NO NO NO Yes 
380 M 28 NO NO NO NO NO NO NO NO NO NO NO NO Yes 
392 M 21 NO NO NO NO NO Yes NO NO NO NO NO NO NO 
393 M 37 NO Yes Yes NO NO NO Yes NO NO NO NO NO NO 
394 M 32 NO NO Yes NO NO NO NO NO NO NO NO NO NO 
410 M 26 NO Yes NO NO NO NO NO NO NO NO Yes NO NO 
426 M 24 NO NO Yes NO NO NO NO NO NO NO NO NO NO 
430 F 44 Yes Yes Yes NO NO NO Yes NO NO NO NO NO Yes 
437     M 33 NO NO NO NO NO NO Yes NO NO NO NO NO NO 
445 M 30 Yes Yes NO NO NO NO Yes  NO NO NO NO NO NO 
448 M 39 Yes Yes Yes NO NO NO Yes NO NO NO NO NO NO 
30 + + + - - - + + - - 
36 + - - - - - - + - - 
37 + - - - - - - + - - 
40 + - - - - - - + - - 
41 + - + - - - + + - - 
42 + - - - - - + + - - 
43 + - - - - + + + - - 
44 + + - - - - - + - - 
50 + - + - - - + + - - 
57 + - - - - - + + - - 
58 + + - - - - + + - - 
59 + - - - - + + + - - 
60 + - - - - - + + - - 
70 + - + - - - + + - - 
78 + - - - - + + + - - 
83 + - - - - - + + - - 
84 + - - - - - + + - - 
85 + + - - - - - + - - 
89 + - - - - - - + - - 
92 + + - - - - + + - - 
95 + - - - - - + + - - 
98 + - - - - - - + - - 
109 + - + - - - + - - - 
118 + - - - - - + - - - 
119 - - - - - - - - + - 
143 - - + - - - + - - - 
149 - - - - - - + - + - 
159 + - - - - - + - - - 
167 + - + - - - + - - + 
171 - + - - - + - - + - 
174 + - - - - - + - - - 
181 - - - - - - + - + - 
190 + - + - - - + - - + 
211     - + - - - - - - - - 
234 - - - - - - - - + + 
250 - - - - - - - - - - 
282 - + - - - - - - + - 
307 + - + - - - + - - - 
320 - + + - - - + - - + 
380 - - - - - - - - - + 
392 - - - - - + - - - - 
393 - + + - - - + - - - 
394 - - + - - - - - - - 
410 - + - - - - - - + - 
426 - - + - - - - - - - 
430 + - + - - - + - - - 
437     - - - - - - + - - + 
445 + - - - - - + - - - 
448 + + + - - - + - - - 
Total 66% 24% 30% 0 0  10% 64% 46% 14% 12% 
50 
 
PBT = Previous Blood Transfused __ BD = Blood donate __OP = operations  
TA = tattooing __ IVDU = intravenous drug users __ AD = alcoholic drink 
RPsc = regular partener sexual contact __ HM = haemodialysis Machine 
INJCN = injured by contaminated needles ___ Sc = sexual contact. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table.14: HBV-DNA and HBsAg in each group. 
No Of Sample    HBsAg HBV -DNA        Tested Groups 
14 + + Haemodialysis Patients 
30 + + Haemodialysis Patients 
36 + + Haemodialysis Patients 
37 + + Haemodialysis Patients 
40 + + Haemodialysis Patients 
41 + + Haemodialysis Patients 
42 + + Haemodialysis Patients 
43 + + Haemodialysis Patients 
44 + + Haemodialysis Patients 
50 + + Haemodialysis Patients 
57 + + Haemodialysis Patients 
58 + + Haemodialysis Patients 
59 + + Haemodialysis Patients 
60 + + Haemodialysis Patients 
70 + + Haemodialysis Patients 
78 + + Haemodialysis Patients 
83 + + Haemodialysis Patients 
84 + + Haemodialysis Patients 
85 + + Haemodialysis Patients 
89 + + Haemodialysis Patients 
92 + + Haemodialysis Patients 
95 + + Haemodialysis Patients 
98 + + Haemodialysis Patients 
109 + + Multi-transfused Patients 
118 + + Multi-transfused Patients 
119 + + Jaundiced Patients 
143 + + Jaundiced Patients 
149 + + Blood Donors 
159 + + Blood Donors 
167 + + Blood Donors 
171 + + Blood Donors 
174 + + Blood Donors 
181 + + Blood Donors 
190 + + Blood Donors 
211 + + Blood Donors 
234 + + Blood Donors 
250 + + Blood Donors 
282 + + Blood Donors 
307 + + Blood Donors 
320 + + Blood Donors 
380 + + Blood Donors 
392 + + Blood Donors 
393 + + Blood Donors 
394 + + Blood Donors 
410 + + Blood Donors 
426 + - Blood Donors 
430 + - Blood Donors 
437 + - Blood Donors 
445 + - Blood Donors 
448 + - Blood Donors 
Total 
5o 
50 45  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table .15:   ELISA, ICT test and PCR results       
No Of 
     Sample 
ELISA   
 Test     
ICT     
Test     
PCR            Tested Groups            
14 + + + Haemodialysis Patients 
30 + + + Haemodialysis Patients 
36 + + + Haemodialysis Patients 
37 + + + Haemodialysis Patients 
40 + + + Haemodialysis Patients 
41 + + + Haemodialysis Patients 
42 + + + Haemodialysis Patients 
43 + + + Haemodialysis Patients 
44 + + + Haemodialysis Patients 
50 + + + Haemodialysis Patients 
57 + + + Haemodialysis Patients 
58 + + + Haemodialysis Patients 
59 + + + Haemodialysis Patients 
60 + + + Haemodialysis Patients 
70 + + + Haemodialysis Patients 
78 + + + Haemodialysis Patients 
83 + + + Haemodialysis Patients 
84 + + + Haemodialysis Patients 
85 + + + Haemodialysis Patients 
89 + + + Haemodialysis Patients 
92 + + + Haemodialysis Patients 
95 + + + Haemodialysis Patients 
98 + + + Haemodialysis Patients 
109 + + + Multi-transfused Patients 
118 + + + Multi-transfused Patients 
119 + + + Jaundiced Patients 
143 + + + Jaundiced Patients 
149 + + + Blood Donors 
159 + + + Blood Donors 
167 + + + Blood Donors 
171 + + + Blood Donors 
174 + + + Blood Donors 
181 + + + Blood Donors 
190 + + + Blood Donors 
211 + + + Blood Donors 
234 + + + Blood Donors 
250 + + + Blood Donors 
282 + + + Blood Donors 
307 + + + Blood Donors 
320 + + + Blood Donors 
380 + + + Blood Donors 
392 + + + Blood Donors 
393 + + + Blood Donors 
394 + + + Blood Donors 
410 + - + Blood Donors 
426 + + - Blood Donors 
430 + + - Blood Donors 
437 + + - Blood Donors 
445 + + - Blood Donors 
448 + + - Blood Donors 
Total 
5o samples 
50 positive 49 positive 45 positive 50 individuals  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix (2) 
Questionnaire 
 
Molecular and Serological Detection of Hepatitis B Virus 
in Risk Groups and Blood donors in Khartoum state and Determination 
of Co-infection with Hepatitis C Virus. 
KHARTOUM STATE 
Questionnaire 
IDENTIFICATION 
Lace NAME:………………………………. 
State:……………………………………….. 
Sample number:………………………….. 
Name of respondent (in pencil):…………. 
Address:……………………………………. 
 
Supervisor:______________________ 
Date:   /     / 
Consent form 
Good morning/afternoon /evening my name is MOAWIA_ELEAD HAMED 
Thank you for taking the time to talk with me. We are from Khartoum University - Graduate college. We 
asking questions to people such as your self at different parts of Khartoum state in our research is detect 
HBV DNA . This research in expected to provide data that may help in medical care of people, who 
contacted this disease. if  you agree to be interviewed, I will be asking you questions about your self, 
your  ideas, attitudes and behavior on various issues. Most of them are related to your disease. in 
addition to this we will be taking some samples (blood), to be for laboratory   investigations. 
Your opinion or experiences  are important to us. We want you to be honest and truthful in answering 
our questions. Your answers will be confidential and secret. if you agree to be interviewed, (you can 
suggest a place to go where no one can hear us talking.) 
Your participation in the study is voluntary. Some of the questions I will ask you some personal and 
about reproductive health, sexuality, blood transfusion and haemodialysis. If you are uncomfortable with 
a question, you don't have to answer if you wish. You may also stop the interview at any time. 
I will first ask you my questions. It will take some time to complete. After that you may ask me 
questions if you want. Is there a place we can go where we can talk? (Suggest a place if the participant 
does not.) Do you have any questions? 
Do you agree to participate in this interview? 
Yes/ No 
Signature of the interviewer:_____________ 
Name of the interviewer:_________________  Date:_________ 
Section 1. Respondent's Background 
No. Questions Answers 
1 Record the time use 24-hour time Hour: Minute: 
2 Sex of respondent Male: Female: 
3 In what month and year were you born? 
Month: 
Don't know month: 
Year : 
Don't know year: 
4 Have you ever attended school? Yes: No: 
5 Are you currently in school? Yes: No: 
6 What is the highest normal school you completed? 
Less than one year: 
primary: 
intermediate: 
secondary: 
University: 
Other: 
7 Can you read or understand a letter or news easily, with difficulty, or not at all? 
Easily: 
With difficulty: 
No at all: 
8 What is your religion? 
Moslem: 
Christian: 
None: 
Other: 
   (specify) 
9 Are you employed? Yes: No: 
10 Tribe  
11 Original place  
12 Have you ever been married or lived with a person? 
Yes married: 
Yes lived with a person: 
No: 
13 Are you currently married or living with someone? 
Yes currently married: 
Yes, living with someone: 
No, Not in union: 
14 
Do you currently have a regular sexual partner, an 
occasional sexual partner, or no sexual partner at 
all? 
Regular sexual partner: 
Occasional sexual partner: 
No sexual partner: 
15 Is your partner living with you now or staying elsewhere? 
Living with : 
Staying elsewhere: 
16 Have you ever had sexual intercourse? Yes: No: 
17 
When was the last time you had sexual intercourse? 
Record "years ago" only if last intercourse was one 
or more years ago (12 or more months ago) 
Record "00" days ago if last intercourse was on 
Days ago : 
Weeks ago: 
Months ago: 
Years ago: 
same day as interview  
18 The last time you had sexual intercourse was a condom used? 
Yes: 
No: 
Never heard of condoms: 
Don’t know: 
Section(  2 ) HBV  
19 HB vaccines Yes: No: 
20 When did this happen Specify: 
21 Haemodialysis Yes: No: 
22 History of Jaundice Yes: No: 
23 History of blood transfusion Yes: No: 
24 Do you know how HBV transmission? (DONOT READ LIST) 
Sexual intercourse: 
Sharing needles and 
blades: 
Blood transfusion: 
Mother to fetus: 
Haemodialysis: 
Other: 
Don't know: 
25 
When frequent do you visit your doctor? Once month: 
More than once month: 
When I feel sick: 
26 Do you follow a specific lifestyle advised by health professional? 
Yes: 
No: 
27 Using anti-HBV treatments Have you ever taken any Anti-HBV treatments  
Yes: 
No: 
28 Have you ever experienced any side effects from anti – HBV treatments? 
Yes: 
No: 
29 Are you taking any Anti-HBV treatments, at the moment? 
Yes: 
No: 
30 At the moment, how many times a day do you have to take any kind of anti-HBV treatment? 
Once a day: 
Twice a day: 
More: 
          (specify) 
  
  
  
Section (3)Media   
31 
Do you usually read a newspaper or magazine 
almost every day, at least once a week, less than 
once a week or not at all? 
Almost every day: 
At least once a week: 
Less than once a week: 
Not at all: 
32 Do you listen to the radio almost every day, at least once a week, less than once a week or not at all? 
Almost every day: 
At least once a week: 
Less than once a week: 
Not at all: 
33 Do you watch television almost every day, at least once a week, less than once a week or not at all? 
Almost every day: 
At least once a week: 
Less than once a week: 
Not at all: 
34 Do you use internet almost every day, at least once a week, less than once a week or not at all? 
Almost every day: 
At least once a week: 
Less than once a week: 
Not at all: 
35 In the past year, have you heard or seen any message about HB? 
Yes: 
No: 
Don't know: 
36 What slogans or messages about HB did you hear or see? 
 
37 
Where did you hear or see these messages? 
(Prompt any thing else 
Record all mentioned 
Selections not mentioned spontaneously)? 
 
Television 
Radio 
Newspapers 
Magazines 
Billboards 
Football match 
Concert 
Community Rally 
Road show 
Tee shirts/ caps 
Moible video 
Tire protector 
Calendar 
Poster 
Sticker 
38 In the past year have you heard or seen any messages about transfusion and haemodealysis? 
Yes: 
No: 
Don't know 
39 
Where did you here or see these messages about 
haemodealysis 
(Prompt any thing else? 
Record all mentioned 
Selections not mentioned spontaneously)  
Television 
Radio 
Newspapers 
Magazines 
Billboards 
Football match 
Concert 
Community Rally 
Road show 
Tee shirts/ caps 
Moible video 
Tire protector 
Calendar 
Poster 
Sticker 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
                                   



 
